Guidelines for the Evaluation and Management of Heart Failure  by unknown
ACC/ TASK FORCE REPORT 
Guidelines for the Evaluation and Management of Heart Failure 
Report of the American College of C s r d i o % o ~ / ~ h e r i c a n  Heart Association Task 
Force on Practice Guidelines (Committee on Evaluation and Management sf 
Heart Failure) 
COMMITTEE MEMBERS 
JOXN F. 'VI'ILLIAMS, JR., MD, FAC.2, Chair MARK A. mATKY, MD, FACC 
MICHAEL X. BRISTGW, MD, FACC CARL iT. LEIER. MD. FACC 
MICEFiEL B. FOWLER, MB, MRCP, FACC MILTON PACKER, MD, FACC 
GARY S. FRANCIS, MD, FACC BERTIIA,M P I R ,  MD, FACC 
ARTHLR GARSON, JR., MD, MPW, FACC BANEL J. ULLYOT, MD, FACC 
BEXXARD J. GERSH, MD, CrrB, DPFIIL, FACC EAKRA F. WEXLEX, MD, FACC 
DONALD F. HAMMER, MD, FACC WILLIAM E. WINTERS, JR., M 3 ,  FACC 
TASK FORCE MEMBERS 
JAMES L. RITCHIE, MD, FACC, Chair 
MELVIN D. CHEITEIK, MD, FACC 
KIM A. EAGLE. MD, FACC 
TIMOTHY 9. GARDNER, MD, FACC 
ARTHUR GARSON. JR., MD, MPH, FACC 
RAYMviOND J. GIBBONS, MD, FACC 
RICHARD P. LEWIS, MD, FACC 
ROBERT A. O'ROURKE, MD, FACC 
THOMAS J. RUAU, MD, FACC 
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1: is i7ecom;ng more apparent eac5 day that despite a strong Gbidelines) with the follo~+ing charge: 
national c o ~ m i ~ m e n t  to excel!ence in health care, the re- The task force of the -ei-ican College of Cardlology 
sourc-s dnd personnel are finire. 11 is, therefore, appropria!e and the fh-Ie~ican &art Associa:*on shall develop guide- 
inct thz medical pro:esslon euaxine the ~mpac: of dzveloping lines relative to  he role of new therapeutic a p p r o a c h  and 
eechnology and n~ iy  lherapeullc lnodii~ilieb on the practice of of spec~fic noninvasi.ve acd ;nvasive proced~ies m eke 
carcbolog. S ~ c h  analysis, carefidlly conductea, could poten- diagnosis and macagemenr of cardiovasc~rlzr disease. 
hall\ have an ~mcacl on rhc cost of medical care piinout Th: task force snaII address, w e n  appropr~ate, the 
diminishing rhe effectivenzss of that care. 
To this end, the American College of Cardiology and the 
American Heart Association In 1980 esrablished a Task Fopce 
on Asseisment of Disgnostic and Therapeutic Cardiovascular 
These gi~iclelines wcrz approved by tne American College o l  Cardioiog 
Board oi 'irasizrs .~nd the Aaerican Heart Ass,~ciation Scizncc Advisory and 
Coo;tiir;,~t;n,i Commitxc in Szptrrnher 1995. 
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contribution, uniqueness, sensirlvdy, specificity, iroicat~ons, 
contrainJlca~ions and cos"r-eBecriveress of such d~agnobric 
proced~res and therapeutlc rngdalities. 
The task force sbaii emphdsize the role anin values of the 
developed gurdellnes as an ed~cahonai nsouice. 
The task fcrcz shall icclude a ch,,ir and eight members, 
i 3 ~ r  representatives irom ine An~encan Hearr As5ociar;sn 
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needed u2on the approv~t; o i  the presidents of both orga- 
0 1905 oy the A *lsrlcan Colle:e oi C'ir,l~o!ogy .inn tne Amer.c In H,-,I~: A\ \~c~dt lon C.735- lI)97/95'$9 50 
- -- -- 0735- '09'195 ,ilOuS9-6 
JACC Vol. 26, No. 5 
hovember 1. 1945: 1376-98 
xizations. Recommendations of tne T a s ~  Force are for- 
warded to the President of each organization. 
The menbo,rs of the :asn force are Melvin D. Ckitlin, MD, 
I(lm A. Eagle, MD, Timothy J .  Gaydner, MD, Arthur Garsox, 
J;., MD, MPH, R a y o a d  3. G ~ D O C S ,  MD. Mic5ard P. 
Lewis, ,219, Rober: A. O'Xourke, &ID, Tnomzs J. Ryan, MD 
and James L. Rltchie, MI), Chair. 
The Cornmirttc io Deveio? Guideiiaes o r  the Evaiuation 
a d  Management of Heart Failure was chaked by John F. 
Ullliazs, Jr.. MD, and included :he foliowling rrernbers: 
Michael R. Brisio\v, MD, Michael 8. Fowler, MB, MRCP, 
Gar) S. Francis, MD, A r t h  Garcon. Jr., MD, MPH, Berfiarci 
J .  Gersh, MB, ChB, DPI-III, Donald F. Hammer, MD, Mark A. 
HIatky) ,WD, Carl '4. Eeier, WD, Miiton Packer, MD, Bertrarr, 
Pit:, MD, D a ~ i e l  J. Ullyot, MD, Zzura F. TVexler, MD and 
William L. Winters, Jr., MD. 
Thrs document vias rcviewed by :he ofice;:, and olhe: 
responsible individna:~ of the h e r i c a n  College of Cardiology 
and American Heart Association and received final apprwvai in 
September 1995. It is being published sirnil?taneotsly in Cir- 
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Task Force on Practice Guidelines 
1 Introduction 
The American College of Cardiology and the American 
Heart Association (ACC have long been involved in the 
joint development of p I I guidelines designed to assist 
1 physicians in the management of selected cardiovascuiar dis- orders or In the selection of certain cardiovascular procedures. ' Selection of the disorders or procedures for which in develop 
guidelines is based on several factors, including their impor- 
tance to physicians and whether there is suscient scientific 
data from which to derive accepted guidelines. 
The importance of congestive hearr failure is underscored 
by the frequency with which the condition is e ed and 
its prognosis, for example, 4.7 million people ES IiI 
I data) in this country have congestive hearr failure, and once 
failure deveiops, tise 6-year mortality rate approaches 80% in 
men and 65% in women (1). importantly, as our population 
ages, the incidence of heart failure and its morralic,~ rate will 
conrinue to increase. Furthermore, recent advances in our 
understanding of the pathophysiology of heart failure and new 
developments in the therapy of this disorder have grea:iy 
expanded the information basc on which to make decisions. 
However, the results of a number of ongoing clinical trials may 
require modification of the reconxnefidations contained herein. 
These guidelines were developed by cardiovascuiar special- 
1 ists and ivere based primarily on a comprehensive review of 
published reports. The references listed are not all inclusivz 
but contain those which we believe are representative of the 
most convincing data. I11 cases where the data do not appcar 
, conclusive, rzcomn~endations are based on ike consensicis 
1 opinion of the group. 
We elected to limit our gcriiielines for adults to heart failure 
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associat-,d with lzft vzntric~lar aysfuncr;on, with the major 
focus on systoiic dysfunction. This dec,sAon was besed on the 
fact tha: the great majority of adults h , r k  kea-t fii::u:e i , ~  this 
cotctry have left ventric~iar sy5tol:c d:~sf~inctian, and the 
greatest adkances .n m r  understanding t;n3 treatment oi heart 
!allure are associated with t h ~ s  disorder. 
The guideli~es for aodts are h s e d  on the rnacner in which 
pdzients present ;o physicians and cncdmpass the extremes of 
presenrarion Som acute pump failure wAtk shock to &symptom- 
ar:c left \rentricslar dysfunction. We habs ir,c!uded pstlenls in 
the latter category beca~se  proper treatment can delay or 
prevent the de\o,:opment oi  heart failire. Treatrne~t s%ra:egies 
frequently depend on :he e:io!ogi of ri;: cisease, and a 
major focui; of these gwdelines is :he diagnosti: approacil ra 
determme correctable etiologies and precipitating factors. 
Wowcter, o w  treztment strafegies do not ~ncluae spccific 
therzples for correctzble cmses of hcart faildre, such as the 
surgical approach to valvular d~sesse or thc treatment of 
rhyrutoxic heart d~sease. 8 ~ r  approach is to discuss the 
diagnostic studies and treatment necessaq to stabilize the 
statuc of adult patient with acuc  heart failure and tne evalu- 
hiion and treatment of parlents presenting with chronic left 
ventri:ular dysfunction or stabilized acute heart failure. 
In the pediatric population, the leading causes of heart 
failure are significantly d~fferent from those in the adu!t. Our 
therapeutic guidelines for the pediatric group therefore are 
directed more to specific causes of heart failure than for the 
adults. 
For both groups, we have followed the format of previous 
guidelines for classifying indications for diagnoscic 
procedures and therapeutic interventions. 
Class I 
Csually indicated, always acceptable 
Class I1 
Acceptable, but of uncertain eficacy and may be conlrover- 
sial 
Class III 
Generally aor indicated 
Because our goal was to develop guideimes for use by 
phys~cians, and our Task Force included on14 physicians. our 
guidelines do not include other aspects of :are, such as nurslng 
care, rekab~!i:~~t~on and ik prs+i~i"cx of social services. Mfe 
recognize thz importaiice of these area> in the overall man- 
agement of paiien:~ nith hearr fajibre. 
The task force did nct drhi nlth :ssues relating to the 
diagnosis of heart failure, nor did we attempr to acalyze the 
cost-eifecticeness of odr recommendations. We gere acurely 
aware of cost ~rnplications of our recommendations, and these 
irnpl:cations were considered in our delrberaciocs. However, 
olir primary god wasto devejop guidelines ro assst physicians 
is dzli\er~ng the hesr care possible to those with h ~ h r t  f.r:lure. 
t+e ernphaslze that t h a z  drc many rilctors, noiabiy ;he 
i+llshes of informed paherits, t h ~ t  ~ifr!rni~tciy ;iererm,i:e the 
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most appropriate therapy for an Indiviriual parient. Therefore, 
deviation from these guidelines may be appropriate in some 
circumstances. Fur iher~~ore ,  rhesc guidelinzs are based on the 
assumption that the resources necessary to provide this care 
are readily available. Unquestionably: this is not true in all 
geographic areas, which further underscores our position  hat 
these are guidelines and not rigid requirerner,cs. 
Acute Heart Failure in Adults 
The clinical presentation of acute heart failure ranges from 
the suddec appearance of dyspnea ro frank cardiogenic shock. 
The rnanagernenr of acute heart failure differs for the various 
patient groups residing within the clinicai spectrum of this 
condition; thus, this topic is approached by separately discuss- 
ing the managementof each of the major clinical groups. 
We assume that the physician has exciuded noncardiac 
disorders whose clinical presentation can be similar in many 
rcspects to that oC acute heart hilure (c.g., noncardiogenic 
pulmonary edema). Also, noncardiac support measures (e.g., 
ver,ti!aror therapy) are not discussed in detail despite the fact 
that these measures are important in the overall management 
of these critically ill patients. 
Acute heart failure can be grouped clinically into acute 
cardiogenic pub??orzuq edema, cardiogenic shock, and acute 
ilecompsaiion of cllronio 1efi heart fai!i~rr. 
W'itk few exceptions, patienrs presenting with acute heart 
failure require hospital admission, parricrilariy those with an 
initial episode of failure (see page 1392). 
Therapeutic interventions ro produce hernodynamic im- 
provement and stability must be undertaken expeditiously in 
these patients. i n  addition, it is imperative to obtain quickly 
those diagnostic tests necessary to detect causes of heart 
failure which are best treated by special therapeutic ap- 
proaches. Myocardial injury/infarction, high degree atrioven- 
tricular (AV) block, ventricular tachycardia, pericardial tam- 
punade and pulmonary embolism are examples of the latter 
causes of failure. Once erioiogies of this type have been 
excinded, further diagnostic testing to determine rhe etiology 
of the heart disease generally cdn be deferred to a more 
appropriate time. 
Acute Cnrdiogenic P~ilmonaty Edema 
A brief medical history and directed physical exarninarion 
are generaljy sufficient to initiate therapy. .An intravenous 
catheter should be placed, blood obtained for essential iabo- 
ratoq studies and the patient placed on oxygen therapy. 
The sublingual administration of nitrogiycerii~ (0.4 to 
O.6 mg, repeated every 5 to i O  min four times as necded) is of 
value. I\iirroglycerin is eRective ir; patients with acuts cardio- 
genic pulmor~arf edema due to both ischemic and nonischemic 
causes. If systemic blood pressure is acceptable (generally a 
sysrolic blood pressure 295 to 101) mm Hg), nitroglycerin can 
be administered intrwerrousiy jstsrfng dose 0.3 to 0.5 pdkg 
body weight per rninj as well ( 2 ) .  
Sodiirm niiropn~ssid,: jsrarting dose U.1 figkg per min) may 
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be selected for patients not immediately responsive to nitrate 
therapy and for those whose pulmonary edema is, in large part, 
attributable to severe mitral or aortic valvular regurgitation or 
marked, systemic hypertension (2). Thz dose is advanced as 
needed ro improve the patient's overaii clinical and hemody- 
nanic status, using a systemic syst~iic pressilre or" 85 ;o 
90 mm Hg ss the usual lower I;mir for dosc incrementation ig 
patients previoiisly normotensive and as kng  as adequate 
perfusion of vital organs is mainrained 
Furoscrnide (20 to 80 mg iatraveeously) should be given 
shorriy after the diagnosis sf acute psimonary edema is 
established. 
Morphine sulfate (3 to 5 n?g inrravenotisiy) is effective in 
ameliorating many of the symptonls a i  a;utc pulmonary edema 
and can be administered safely ro must patients with this 
condition. Woivever, morphine sulfate should be admiristered 
with caution to patients %itin chronic ps;lr;lonary insuficiency 
and those with respiratory or metabolic acidosis in whom 
supprzssion of ventilatory drive can cause a drastic lowering of 
systemic pH. 
Intubation and mechanical ventilation are of value in 
patients with severe hypoxia that does not respond rapidly to 
therapy and in those with respiratory acidosis. 
Patients with severe refractory puimonary edema may 
benefit from intraaortic bailooli counterpulsation (see page 
1382). This procedure is of particular value if the patient is to 
undergo urgent cardiac catheterizaiion and definitive interven- 
tion. Intraaoriic bailoon colinterpuisarion should not be used 
in patients with significant aortic valvular insufficiency or aortic 
dissection. A rare patient presenting with severe refractory 
pulmonary edema and a correctable lesion may need to 
proceed directly to the operaiipig room after prompt diagnosis 
(usually by clinical examination and ecbocardiographyj of rhe 
precipitating lesion; examples include rupture of a papillary 
muscle with acute, marked mitraI regurgitation and acute 
aortic dissection complicated by proximal coronary artery 
occlusion or marked aortic vaivuiar insuficiency, or both. 
Patients who develop cardiogenic shock should be approached 
as discussed later. 
In most patients acute cardiogenic pulmonary edema can be 
stabilized with appropriate intervention arid frequent, inter- 
mittent bedside eilaluation without the routine inuoducrion of 
icdwelling pulmonary or systemk arterial ciitheters. "Placement 
of a puimonary artery bailoon catheter should be considered in 
this se t i i~~g if I )  the patiefit's clinical course is deteriorating; 2 )  
recovery from the aciite presentation is aor proceeding as 
expected; 3) high dose nitroglycerin or nirroprusside is re- 
quired for clinical stabilization; 4) dobiltaminc or dopamine 
are needed to augment systemic blood pressure and peripheral 
perfusion; or 5) uncertainty exists regardi~g the diagnosis of 
acute cardiogenic pulmonary edema (see page 1382). 
Early in tht initial evaluation of patients with acute pulmo- 
nary edema, the physician must determine whether acute 
myocardial irijury.'infarction is present. At this stage, this 
determination is based on clinical assessment and the elec- 
trocardiogram (ECG). Evidence of acute myocardial injury/ 
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infarction should raise consideration of urgent myocardiai 
reperfusion therapy. Cardiac catheterization and coronary 
arteriography fo'ollowed by trhr: most appropriate interventions! 
procedure (if readily available), or rhrombolytic therapy 
should be considered. The reader is referred to other ACCI 
AHA guidelines (3-5) for additional, more specific informa- 
tion regarding the therapeutic approach to acute myocardial 
injuqdinfarction. 
Transthoracic Doppler-two dimensional echocardiography 
is indicated in ail patients who present with acute cardiogenic 
pulmonary edema, uniess there are obvious precipitating fac- 
tors and <he patient's cardiac status had Seen adequately 
evaluated przviw;s!y. Depending on ";he urgency for confirming 
or establishing a diagnosis, the procedure is performed as soon 
as possible after initial stabilization. Transesophageal echocar- 
diogrdphy inay be required to diagnose or more cfearly define 
certain lzsions (e.g., ruptured chordae tendinca, aortic dissec- 
tion). 
Initial Diagnostic Evaluation of Acute 
P~tEmonaq) Edema 
Class I 
1. Focused historyiphysical examination 
2. 1Zlcad ECG 
3. Continuous ECG monitoring 
4. Blood-serum studies: complete blood count (CBC); 
electrolytes, blood urea nitrogen (BUN), creatinine and car- 
diac enzyme levels 
5. Digital pulse oximctryiarterial blood gases 
6. Chest radiograph 
7. Transthoracic Doppler-two dimensional echocardiogra- 
~ f i ~  
8. Cardiac catheterizationlcoronary arteriography for sus- 
pected coronary artery disease 1) if acute intervention for 
myocardial injurylinfdrction is anticipated; 2) to determine the 
causejs) for refractor?, acute pulmonary edema 
Class II 
1. Indwelling arterial cannula 
2. Transesophageal echocardiography 
3. Tabulation of fluid volume intake and urine output 
Class III 
Extensive evaluation (e.g., cardiac cathererizazion and cor- 
onary arteriographyi in a patient with a concomirant terminal 
illness or who iirvuld not be considertd a candidare for h e  
necessary major cardiovascuiar intenrention. 
Therapeutic Management of Actt te 
Pulmonay Edernu 
Class 1 
1. Oxygen therapy 
2. Nitroglycerin. sublmgual!y or intravenously 
3. Ir,travenous administration of a diuretic (z.g. furo- 
sernide) 
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4. Morphine sulfate 
5. Administration of cardiovascular siipporl dri~gs to azrain 
and stabilize clinical-hernodynamic staeus je.g., intravenous 
infusion of nirroprusside, dobutarnine, dopamine) 
6~ Thromboiytic therapy or urgent icvascularizadon jan- 
gioplasty or coronary arccry bypass surgeiyj for acute myocar- 
diai inLjuqlinfarctiox 
7. Intubation an3 mechanical ventiiation for severe hypoxia 
that does not respond rapidly to therapy and for respiratory 
acidcsis 
8. Definitive correction of the underlying cause (e.g., rnitral 
valve replacement ar repair of acjlite, szicrc rnitral reggrgita- 
tion) when indicated and clicicaliy feasi9ie 
Additional cardiovascular Iaborctory testing nay be neces- 
sary to exclude correctable causes of hesrt failure once the 
patient's status is siabihzed, as d i~cus~zd in rhe section on 
chronic and stabilized acdte heart iaiiure. Without the detec- 
tion and correction of a reversible cause or lei;iiin, the iong- 
term prognosis of patients w k ~  present rv:th acute cardiogeaic 
pulmonary edema is poor (6). 
Gardiogenic Shock 
If cardiogenic shock is not caused by a reparable lesion, or 
if the lesion is not repaired in an efficient and effective manner, 
the mortality rate is 285% (7,8). Therefore, cardiogenic shock 
should be approached with diagnostic and rherapeutic vigor in 
an attempt to identify a treatable lesion and to intervene in a 
definitive manner. Patients presenting with hypoperfirsion but 
adequate blood pressure may be considered to be in near 
shock and should be approached in the same manner to 
prevent the progression to frank shock and death. 
The genera? principles of management are rapid recogni- 
tion d the condition; rapid exclusiun or treatment, or both, of 
readily reversible causes; and prompt stabilization of the 
clinical and hernodynamic status. .4s in most emergency situ- 
ations, many of these activities are performed simultaneously 
without a routine or set sequence for all patients. 
An ECG should he obtained, continuous ECG monitoring 
instituted, an intravenous catheter inserted and an indwelling 
arterial cannula placed for continuous 'blood pressure moni- 
toring. An indwelling pulmonary artery catheter shollld be 
inserted at an early stage of shock management, unless the 
patient responds rapidly to fluid infusion. The catheter should 
be inserted by an operator skilied in this ~schnlyue in a suitable 
environment (e.g., procedure room of the emergency depart- 
ment, intensive care unit or catheterization lahoraiory), with 
assistance from experienced staff. 
If arrhythmias are present, their contribution to the hemo- 
dpamic state and need for rapid cardioversion or pacing must 
be determined. 
In patients presenting with cardiogenic shock, 2 relative or 
absolute red~iction in IzFt ventricular filling pressure as the 
cause of hypotension must he excluded. Because of prior 
diuretic therapy or acute interspace volume shifts, it is esri- 
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mated that 10% to 15% of patients with an acute myocardial 
Infarction nay  be significantly volume depleted (7,9). Right 
vectrizular infarction, pericardial tamponacle and certain in- 
stinces of pulmonary embolizarion are other common cxarn- 
pjes of acute hearr failure that fall into this category. Unless 
there are signs of left heart volilme overioad je.g., S, galbog, 
moist piilrnonary ra!es, vascular or pulmonary congestion on 
chest radiograph), normal salirie solxion shotild be adminis- 
tered intravenoi?siy at a reasonably fast rate (2500-mi bolus, 
foliowed by 500 ml!h). Sugdlar venous pressure is not a 
coi~sistenily reliable indicator of left heart filling pressure (ID), 
and, thus, elevation of jugular pressnre does not obviate rBe 
need for Auid administration in a number of clinical situations 
(c.g., pericardial tamponade, righr ventricular myocardial in- 
farction). 
In patients with an acute inferior infarction with shock, a 
right ventricular infarcrio~~ should be suspected, resulting in 
right ventricular failure and inadequate filling of the left heart 
system. Right-sided precordjal ECG leads in addition to the 
standard leads should be used in these patients. An injury 
pattern is often but not uniformly observed on the right 
precordiai lead tracings (V,R, V,R) in patients with a right 
ventricular infarction. The diagnosis of right ventricular infarc- 
tion frequently can be made on the basis of clinical findings 
such as an increase in jugular venous pressure during inspira- 
tion. An echocardiogram or the insertion of a pulmonary 
artery balioon catbetcr, or both, are helpful in patients in 
whom the diagnosis is unc!ear. Right-sided cardiac pressure 
recordings generally show mean right atrial and right ventric- 
ular filling pressures equaling ar exceeding pulmonary artery 
occlusive (wedge) pressure with normal or low pulmonary 
artery pressures (11-13). Echocardiography can be used to 
establish or confirm the presence of right heart imloivement, 
assess tricuspid valve competence, evaluate the extent of left 
heart damage and left ventricular function and exclude peri- 
cardial tamponade (~vhich can have a similar clinical presen- 
tation). As an alternative, radionuclide angiographp can be 
used to detect right ventricular infarction by demonstrating 
right ventricular enIargeillenr and dysfunction. 
FIuid volume administration is a major component of 
therapy for parients with right ventricular infarction to main- 
tain the elevated right-sided filling pressure necessary to 
maintain cardiac output. Flnid administration initially may be 
guided by clinical variables je.g., systemic blood pressure, 
peripheral perfasion, urine ofitput, ventricular gallop sounds), 
but hernodynamic monitoring by a pulmonary artery catheter is 
gensrally required to optimize voiunle adrninistrarion. Failure 
of fluid volume administration to achieve clinical and hemo- 
dynamic improvement and stabilization in these patients re- 
quires additional thcrapeuiic approaches (e.g., dobutamine, 
intraaortii balloon counterpuisation or interventional proce- 
dures). The use of diuretic drugs or \wmliiator agents in 
patients wirh a right ventricular infarction can result in severe 
hypotension. 
Occasionally, vasoclilalor agents and ciiil~riic drugs produce 
hypotension iri paiicors ivirh an acutz myocardial infarction 
and pulnonaq edema becasue tne translocaetar; of fl,iid into 
the !ung reduccs int~avascular volume. Tnese patimts sflould 
be treated as described ia:er. 
Severe hypotenalon (systolic blood pressux 2711 mm Wg] 
or ciinlcal chock, or both, occurring in the presence of volume 
overload or persisting after ~ o i u s  alm,: admm:s:raiion should 
be approached with moderste (4 to 5 pg'kg sody weight per 
min), then, if necessary, ncrcaslng doses of h p a r n i ~ e  (14,IS). 
If hypotension or clinical s3ock or cear mock persists at 
doparnine doses 315 pg,kg per min, i2stiiut;on of lntraaorfic 
balloon coilnterpuhation should be considered for patients 
wirh a poien:ial:y reve-sible condition or as a bridge to 
transplanlabon. Tf intradortic balloon cour;:erpu!sat:on ,s not 
wailable, norepinephrine can be auded to izcrease systemic 
blood przasure lo acceptable letel5 (bystol:c pressure 
2% mrr; Hg) hnd the p i ient  iransfcrred on an emergency 
bas~s to a more comprenensi~!e rnedicd fac,hty. Pat:en"i swlrh 
volume overload (or after adequate volume loadhg) in near 
shock or with a les$e: degree of systemic 5jpotension often 
respond favorably to dobutarnine (2 to 3 ~g!kg per min 
Initially) or !ow to moderate doses of bopam:ne (2 to 5 pgkg 
per min initially) (14,151. 
During treatment, attention should remain focused on I)  
the status of the parient's intravascular volume; 2) the condi- 
, 
tion of the patient's ventr~cuiar function; 3) the presence of 
myocardial injuq:mfarction, and 1) nhether correctable, me- 
chanical lesions are present. 
I. Status of inlravascular volume. The best means of 
assessing and monitoring intravascular voiume in lhese pa- 
:ients is by heniodjnamic measurements ihrough the puirno- 
nary artery catheter. However, in the presence of left ventric- 
ular dysfunction, the usual pressure criteria used to assess ; 
intravascillar virlilme do not apply. The opr~inal eft ven~ricuiar 
diastolic filling pressure, as estimated by the pulmonary artery- 
occlusive (wedge) pressure (or pulmonaq artery diastolic I 
pressure when comparable), for most patients with shock or I 
near shock secondav to acute myocardial iciarctlon resides 
between 14 to 18 mrn Hg (16). 
2. Status of patient's \entricnlar function. Tranntnoracic 
Doppler-rwo dimensional echocardiography is helpful in as- 
scsslng the status of vzntricular funct~on and guidlng additiocal 
sadies and interventioas. The &ding of segmenthi Liiypohne- I 
sia or akinesia suggests the presence of occlusive curonan' 
ertery drsease, a:tl-iough qinilar findings ~1164 occdr in some 
patients with acute rnjocarditis or idiopathic dilated cardio- 
nlyopathp. Gioba, left ventriciliar enlargement and dysf~nction 
generally indicate a more difluse or chronlc process. 
The thermodlldtion pulmonary artery catheter can provide 
diagnostic information and a general functional assessment of 
venrricular and overail cardiovascular performnce. Deprtssed , 
stroke volume ir, the settrng of eievatei-i pulmonarj arte? 
occlusive @edge) pressiirc generally mdicares a c~gniiicant 
reJlic?iori in lett ventricular funct~an. EIe\.idicri V jsys;olic) 
wales nn the wedge p ~ s i t ~ o n  suggest the preqznce of miria! 
regiirgtailon, although : h ~  absence of elevatea V wales dues 
not excl-iide rnitrai regurgitation. Significant oxygen desatura- 
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tion in mixed venous blood drawn from the pulmonary artcry 
indicates depressed systemic oxygen delivery. 
3. Existence of myocardial injuqlinfarction. Emergency 
cardiac catheterization and seiectivc coronary arteriography 
should be considered in the patient with cardiogenic shock or 
near shock and ECG evidence of amre myocardial injuqfin- 
farction (3,17-i9j. Reperfusion of the illjuredllnfarcied r eg io~  
of the &cutely occluded coronary artery in patients wirh shock 
301 responding to Auid administration >as been reported (20) 
to reduce rhe mortality rate from <85% to 560%. Ideally, the 
patient is transferred to the catheterization laboratory shortly 
after initid stabilization. In patients in near shock/shock who 
do not respond to Auid adminisiration and cannot undergo 
=atheterization-intericntion expeditiously, thromholyric ther- 
apy should be considered. Admittedly the effect of thrombo- 
lytic therapy on mortaliq under these conditions is unclear. 
4. Are correctabie, mechanical lesions present? Clinical 
evaluation and rransihoracic Doppler-two dimensional echo- 
cardiography are the primary methods to diagnose or exclude 
most of these lesions ini;ially. The nost commonly encoun- 
tered potentially reversible defects in this clinical setting are 
pericardiai tamponade; massive pulmonary embolism; rupture 
of ckordae tendinae, papillary muscle or ventricular septum; 
critical valvular stenosls or acute regurgitation; aortic dissec- I tion with complicating lesions (e.g.. acute coronary occlusion, 
acute aortic valiular regurgitation); acute obstruction or in- 
competency of a prosthetic heart valve; and cardiac tumors. 
Additional diagnostic testing, such as transesophageal ccho- 
cardiography and cardiac catheterization may be necessary to 1 more precisely define the lesion(s) and disease precess before 
definitive surgical intervention. 
Initial Diagnostic Evafuatiorz of Cardiogenic 
, ShockI~Veur Shock 
I 
Class 1 
I. Focused history-physical examination 
2. Twelve-lead ECG (plus occasional right-sided leads) 
3. Contmuous ECG rnonitor~ng 
4. Blood-serum studies: complete blood count, platelet 
count, clotting studies, electrolytes, BUK, crea:inine, glucose 
and cardiac and liver enzymes 
5. Arterial blood gases and lactate concentration 
6. Chest radiograph 
7. Transrhoracic Doppler-two dimensional echocardiogrd- 
P ~ Y  
8. lndweilfng arrerial cannula for con:inuous monitoring oi  
systemic $loud pressure and for arterial blood gas sampling 
9. Tabulation of fluid volume intake, urine output and 
other fluid volume loss 
10. Cardiac catheterizarionlcoronar)' arreriography if acute 
revascularizatior, for acute myocardial inju&infarcrion is an- 
~icipated 
Class II 
Transesophageal echocardiography 
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Class III 
Extensive evaluziion in a patient with a concomitant terminal 
illness or who is riot ii candidate for cardlovascul~r intenlenrion 
Therapeutic Management of Curdiogenic 
Shockl:tTeay Shock 
Class 1 
1. Oygec  tkerapy 
2. In ;he ahseccz of obvious intravascuiar volume overload, 
brisk i~travenoas administrat~on of Muid volume 
3. In the presence of inirwascular volume ~vei-load or after 
adequate intravecous fluid voiuxe the;apy, intravenous ad- 
ministration of cardiovascuiar support drugs (e.g.. dopan~ce,  
dobutamice, norepinephrine) to a::a:n silcl mhinlain stable 
clinical- hernodynamic stat us 
4. Lrgenr coronary artery revascu1anzat;on fo; acute myo- 
cardial inJurJliicfzrction, if readily available 
Class I1 
1. Thromboiytic therapy in the setting of acute myocardial 
injutylinfarction if a cardiac catheterizationlco~onary arteriog- 
raphylrevascularization procedure is not readily available 
2. Ventricular assist device in patients who respond inade- 
quately to the aforementioned interventions and who are 
reasonable candidates for heart transplantation 
Class III 
Extensive evaluation and major intervention in patients 
with a concomitant terminal illness, those aflicted wirh an 
irreversible underlying cause or those who are not candidates 
for corrective intewmtion or heart crai~splantarion 
Acute Decompensation of Chronic Congestive 
Hearl Failure 
The general principles of management for this group of 
patients are clinical and hernodynamic stabilization, diagnostic 
studies for reversible precipitating iacror(s) and optimization 
of long-term therapy. 
The ciinicai manifestations of this group of patients gener- 
ally are secondary to volume averlaad, elevated ventricular 
filling pressures and depressed cardiac output. 
iMiM to moderate symptoms can be treated effectively with 
intravefiously or orally ad~inistereci diuretic drugs and rein- 
stiturion or optimization, or both, of the patients' long-term 
therapy for chronlc heart failure. Unless the presentation i5 
compllcated by a precip~tating factor (e.g., recent myocardial 
infarction) or a concurrent threatening condition je.g., marked 
hypokalemia, moderate lo marked azofemia, symptoinatic 
arrhythmias), many of these patients do cot require urgent 
ho.;pitJ admission Seyond sekerai hours of obsenzrion in ac  
emergency room or outparienr tacihty. 
illoderate ti;. m e r e  f~mplorris usually require hospital admis- 
son,  generally In 3 cardiac or intensive care ticit. The diagnos- 
tic rind therapeutic approach is similar ro :h,tt fur patiens 
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presectirig with acute heart failure. Once symptoms at rest are 3. As a diagcosdc tool to resolve any ~ncertainijr of 
largely alleviated, and reasonable clinical znd hernodynamic whether pujmonaq zderna is cardkg~zic  or noncardiogecic ir. 
srabii~tj is ache\ ed fcr 224 ii, any intrave~ously adn~inistered or~glf; 
cardiovascular support drugs cac be withdra\vn (ssually in s 
deci-emental manner) while orally adninistcred !ong-tcm 
heart failure therapy is optimized. 
The ucderlying cardiac diagnosis has been esta'siished for 
the majority of psrients in this group, axd the precipitating 
factors usually Cali bc ascertained by history, physical exami- 
nation, electrocardiography, serial cardiac enzyme level deter- 
minations, an echocardiogram and selected laboratory testing. 
Extensive diagnostic evaluation Is generaiiy not necessary if 
correctabie causes of heart failure have Seen excluded previ- 
0Lisll;. 
Recommendations for intuaaortic Balloon 
Counterp~~lsalion i 1Yeaul Failure 
Class I 
1. Cardiogenic shock, pulmonapy edema and other acute 
heart failure conditions not responding to the proper admin- 
istration of fluid volume or phamacologic therapy, or both, in 
patients ~ i t h  potentially revsrsible heart failure or as a bridge 
to heart transplantation 
2. Acute hearr faiiure accompanied by refractory ischemia, 
in preparation for cardiac catheterization/coronary arteriogra- 
phy and definitive intervention 
3. ,Acute heart failure complicated by significant mitral 
regurgiiation or rupture of the venrriclilar septum: to obtain 
hernodynamic stabilization for definitive diagnostic studies or 
intervention. or both 
Class HI 
Progressive, chronic heart failure if necessary ro allow for a 
proper diagnostic approach, time to consider treatment op- 
tions and definitive intervention (e.g., cardiac surgery, keart 
transplantation). 
Class III 
1. Significant aortic insufficiency 
2. Aortic dissection 
3. Patients unresponsive to therapy in whom <he cause is 
to be uncorrecfable or irre\lersible and v~ho  are noi 
candidates for transplanration 
4. Patients in the end-stage of a "irminal illness 
5.  Bleeding diathesis or severe thrombocytopenia 
Recommends tions lor Pllicernent of Pulmona?y 
A r i e ~  Balloon Catheter in Hea?? Fnil~~re 
Class 1 
1. Cardiogenic shock or near shock that does not respond 
promptly ro the proper administration 0:' fiuld volume 
2.  Acute pulmonay edema that does 1101 rcspond :o ap- 
propriate ineervention or rs coaplicatea by system~c hypoten- 
$ion or $hock near shock 
Class I I  
;. Assessment of the statcs of intrzva~c~iicr volume, ven- 
tricular filling pressures and overall card~i,c s'kcctior: in a 
par:ent whobe dzcompensateo ckranic 5ear; faiicx is not 
responding a2propria:eiy to s:ar,dard therapy 
2. Evaluation of overall sar~liac-hemod>i)3am;i statLs and 
exclusion of left hearr fa~lure rn a patier.1 w i n  decornpens2ted 
cnronic I;rg disease 
3. As a d~agnosric :ocl :o assess the origii; and c~~nlcs l  and 
fiemodynam;~ sigsdcance of a 2ew systolic murmur in acute 
heart faiiure 
Class ZHI 
As a routine app:oack to the assessment, diagnosis or 
treatment of heart failure 
c Patients presenting with acute heart failure usually should be 
admitted to the hospital. Initial diagnostic testing for pa- 
tients with acute heartfa~lure should be liml~ed to those tests 
nec<ssar)l to exclude et~oiogies requiring spccial therapeutic 
procedures. Further diagnostic lestlng generally can be 
deferred until hernoilqmarnic stability and improvement have 
been atiaiiled. 
r Initial laboratory testing generally can Be limited to CBC, 
ur~nalysis. serum electrolytes, creatinine. cardiac enzymes, 
blood urea nitrogen, arterial gases and pH, ECG, chest 
radiograph, and transthorac~c Doppler-two dimensional 
echocardiograpky. 
Parients with acute heart failure hnd evidence of acute 
myocardial i:-qury/infarction should be considered for urgent 
cardiac cathererizat~on, coronary arreriography and defini- 
tive intencnnonal procedures. Thrombo:ysisssBould be con- 
qiciered if these studies cannot be done e,uq?edi;iousiy. 
s Treatment of acute cardiogenic pulmon~ry edema consists 
initially of intravenous dicretic drugs, nitrates, oxygen and 
morphine. Intubation and mechanical lentilation are of 1 
value in celecred patients. 
e Pttients wi;h cardiogenic shock who do net have evidence of 
volume overload should reccive a rapid izfizsion of intrtlve- 1 
nous fluids isitialiy and tke response obser>izd. 
a Patients with cardiogenic shock unresponsi~ e to fluid admin- 
lstratlon or viho have obvious volume overload shoald be 
gil en intravenaus dopamine :nit~ally. 
r A puimonary artery balloon flotation catheter shouid be 
inszrted in all patients tilth cardiogenic shock unless there is 
rapid response no fluid ad~2.3;nistration. Patients with acute 
cardiogenic p~ lmonap  edema generally do cot require a 
puirnonhry artery carherer. Honever, catheter mszrnon is 
ind~;~;ted in i,h.oc;e not :espondi~;g appopnafely :o therapy 
or nhirse in \ ; v i ~ ~ m  ills unclear whether ihe pui~aon,tq edema 
IS due to cardisc or noncardiac ca,lses. 
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.a Ifitraaortic balloon counterpulsation may be indicated in 
patients with acute heart failure not responding adequately 
to therapy. The device is parricuiarly helpful in attaining 
hernodynamic improvement and stability while awaiting 
additional diagnostic or therapeutic intzrventicns. 
Chronic and StabiIiaed Acute Heart Failure 
in Adults 
Systolic Dysfinctior,: Evai~~ntion 
A1 patlects presenting with chronic heart failcre should 
undergo a diagnostic evab~ation that shouid be lirnitcd initia$ 
to those btudies necessary to 4)  determine the type of cardiac 
dysfuncrioc, 2) urcover correctable etiologic factors, 3) deter- 
mine prognosis, an3 4) gnide treatment. A similar approac3 
<houla be applied to patients with acute failure if not ade- 
quately evaluated during the stabilization phase. Transthoracic 
Doppler-two dimensional echocardiography is of particular 
benefit in the initial evaludtion of patients with heart f a k e  to 
specifically assess ventricular mass, chamber size and systolic 
and diastolic function and to search for causes best treated by 
specific therapy (e.g. aortic srenosis, segmental systolic con- 
traction abnormaIiries suggestive of occlusive coronary artery 
disease). Magnetic resonance imaging (MRI) is a promising 
diagnostic tool to assess ventricular function and mass and 
1 to detect structural abnormalities. However, the cost- 
effectiveness of MRI in relation to other more readily available 
diagnostic modalities has not been adequately evaluated. I The most commonly identified causes of left ventricular 
systolic dysfunction in the United States are coronaq artery 
disease, hypertension and idiopathic dilated cardiomyopathy 
(21). As the available treatment modalities for hypertension 
have Improved, and large-scale detection programs have re- 
sulted in wider application of aggressive treatment to the 
general population, ischemic hearr disease has become the 
most common cause of hean failure in adults (22). 
The combination of ischemia and left ventricular dysfunc- 
tion (with or without overt clinical hearr failure) carries a poor 
prognosis, and it is this subset which stands to ggain the greatest 
benefit from revascuiarization (5). In some patients with 
coronary artery disease, left ventricular systoiic dysfunction 
may reflect the reversible effew of intermittent or prolonged 
isckernis ("myocardial stunning'' or "liibernation"). For exam- 
ple, survivors of a nyocardiB1 infarction rn.q show evidence of 
"hibernating" myocardium, that is, hypokinetic, hjrpoperfused 
myocardial areas that are still viable and improve after reper- 
fusion. Even patients with very severe left ventricuiar dysfunc- 
tion (ejection fraction <15% to 20%) may show significant 
improvement in ejection fraction and functional state affer 
revascularizarion of hibernating qoca rd i~ im (23). 
Patients with angina and moderate to severe left ventricular 
systoiic dysfunction, inciudirig those with congestive hearr 
failure have been shown ro have inproved survival after 
I 
I coronary bypass surgery (24). Based on these data, coronsl-y 
arreriography sho~ild be strongly considered in patients with 
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coexistent angina and congestivz heart faiiure to assess %it- 
ability f ~ r  coronary revascularization. 
Patients with prior myocardial infarction and congestive 
heart failure but without angina are ~ornmcnly evaluated with 
noninvasive testing to detect ischemia or Sbernating myocar- 
diuln o i  with coronary arteriograpkj to document the extent of 
coronary artery disease. However7 coronap revascu!arization 
has not been shown (24) to imprwte survival in patients with 
coronary artery disease and heart faiiure withoat angina, 
although regional ventricular function n-12,~ improve. Although 
there is a strong pathophysiologic basis to anticipate that 
pztients with evidence of extefisive myocardial ischemia or 
large areas of hibernating myocardium would benefit from 
coronaq revascularization, there are no data from randomized 
trials directly relevant to patients with heart failure. Analysis of 
observational data suggests that the poe:n:ial benefi: of coro- 
nary revascu!zrization is directly proporiional to the extent of 
ischemic but noninfarcted myocardium that can be revascular- 
ized. 
In the absence of angina or prior ~yocardiai  nfarction, rhe 
probability of coronary artery disease as the cause of heart 
failure varies considerably among patients. After clinical as- 
sessment, the physician properly may elect to 1) not pursue 
further testing for coronary disease, 2) use noninvasive tests to 
detect myocardial ischemia, or 3) perform coronary arteriog- 
raphy. There are insuficient data at present to evaluate the 
relative efieacy of these alternative approaches. However, a 
more aggressive diagnostic approach can be justified as the 
probability of coronary artery disease increases (e.g., in pa- 
tients vith multiple risk factors or regional wail abnormalities 
on echocardiographyj. 
Several noninvasive tests are available to detect ischemic or 
hibernating myocardium. Guidelines for the use of radionu- 
dide imaging to detect these conditions have been published 
recently (25). The "gold standard" for the identification of 
myocardial viabiliq is positron emission tomography, which is 
costly and not generally available. Noweve;, quantitative thal- 
lium scintigraphy using exercise with lat: redistribution or 
reinjection at rest imaging as well as rest-redistribution imag- 
ing may provide most of the clinically relevant information 
regarding viable myocardium in patients with left ventricular 
dysfunction. Technetium-99m sesramibi is of value in measur- 
ing ventricular funcrion and detecting ischemia but appears to 
be of lesser value in assessing myocardial viability. Tharmaco- 
logic means for inducing "ischemia," such as the use of 
dipyridamole, dobutarnine or adenosine, are useful in patients 
vilho cannot exercise. Stress echocardiography using exercise or 
dobutamine is an alternate approach for detecting ischemia 
(261, as is dobutamine echocardiography for assessing myocar- 
dial viability (27). 
Patients whose heart failure cannor clearly be attributed to 
hypertension or coronary artery diszase should undergo a 
diligent evaluation for other specific etioiogics; the designation 
"idiopathic dilated cardion~yopatily" should only be applied as 
a dtdgnosis of exciusion after ar, appropri:tle evaluation has 
been completed. Table 1 presents a partial list nl  specific brit 
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Table 1. Less Common Causes of Left VentncuIar 
Swroliz Dpsfunciior; 
- 
I l i j ~ c t i o ~  a p t s :  vix l ,  hac;edal, fucgai 
Acute rhe~ln~ctic fcger 
It~$ltratiie dborders: anyloid, hemochrornarosis, sarcoid 
Toxic: heroin, cocai~e,  alcohol, amphetamines, adriarnycin, ~~cl:~pnosphemicie, 
sujfonamidcs, iecd, arsc~ic, coaalt, phi~sphoms. ethyl:r,c glycol 
,Vutri;ional dr;iciencies: p:oi-,in, thiernine, scle~itirn 
E!rctroiyte disorders: hypocalcernia, h:~pophosphaternia, hyponatremia, 
hypokaiernia 
Collagen vasclllar dBorders: iupus crythematostis, rheumatoid ar;hiitis, systemic 
sclerosis, poiyarteritis nodosa, hy?ersensitiv;iy vascr;!i:is, Takayasu's 
syndrome, polympsitis, Reiter's syildrome 
Erdocrine and n:etnbo!ic dkeases: diabetes, thyroid disease (both hypo- 2nd 
hyper-j, hypopararhyroidism with hypcwlcemia, pkeoci;rornocytcrna, 
acromegaiy 
Tachycardia induced: inccssan; supraven;rlci~lar rachyar:$ihmias or atrial 
fi!brillarion with rapid ven::iculzr ri,tzs 
?/lxce!laneous: hypereosinophilic syndrome, peripart-m aardiomjpathy, sleep 
aplisa sjrtdrome, IYhipple's tisezse, ~- i i in i ; i i~e  dsficieficy 
less common etiologies of dilated cardiornyopathy; clinical 
features of these disorders have been reviewed extensively 
elsewhere (28,23). However, c!inical judgment 1s called for 
when determining the extent to which other diagnoses should 
be pursued There is usually little justification for aggressi%ely 
pursuing conditions whose incidence is exceedingly low or for 
which there is no specific treatment unless there are other 
specific justifications for determining precise etiology (e.g., 
candidacy for transplantation), The diagnosr~c pursuit of such 
cond~tions hould be based on a htgh index 01 suspicion raised 
by other clinical or laboratoy findmgs. 
Myocardltis frequently is considered in those with unex- 
plained heart failure, particularly if the patients are young and 
the failure of acute onset. However myocardiris is an ancorn- 
rson cause of heart failure. Infectious agents may cause heart 
failure by their direct effects on myocardial tissue or by 
triggering an immune response that presents as an acute 
mflammatory rnyocarditis or as a delayed response causing 
late, slowly progressively dysfuncilon. Myocarditls (often w ~ t h  
pericarditis) usually is a mild. self-limited disease in which 
cardiac dyshncrioil is eompietely reversible. Fdhinanr mjo- 
carditis with progressive, irreversible heart faiiure as an Imme- 
diate and direct result of viral infection 15 relatively rare. 
Efforts ro develop noninvlisive mernods to screex heart 
failure patients for acute rcjocardiris have not been success5~1. 
A variety o i  radionuclide techniques have been proposed hut 
either remain 1nve8;tigational or lack the sensirlvlty and speci- 
ficity to be clinically usefni (25). Simiiarlj~, increas~ng serum 
t u  A r s  of antibody to a specific viral agent may provide circum- 
stantial evldence for acute viral mgocardrtis but are of little 
help clinically. Biopsy evidence of significant inflammation and 
m)acardial necrosis is required to provz the diagrios~s of acute 
myocarditis. When strict histologic criteria for active rnyocar- 
dit~s are applied (301, the y~eld 19 iovt (510%) among patients 
wirh systolic dysfunction and congestive hear: faliu:e O F  recent 
dnse~  (31.32). Most importam, the recentiy reported Myocar- 
ditis Treatment Trial (32) found no beneficiai eBecl of pred- 
nisone with eitller azathioprine or cyclosporiac in patients with 
biopsy-proven lyrnphocytic myocarditis. However, 3s the inves- 
tigators sore, the study does not exclude a beneficial effcc? of 
orher i m m i i n o s s s i v e  regimens or therapies in other forms 
of rnyocarditls or at other stages of the diseasz process. 
Recommended Routine Di~gnostic Studies for 
Adult Patients With Chronic Heart Failure or 
St~~Lzhiilzed Acute Heart Faiiure Not 
Previously Be~fonxeu" 
Class I 
1. CBC and urinalysis 
2.  Blood-serum: electrolytes, SUK, creatinine, glbcose, 
phosphorus, magnesium, calcium and aibunin levels 
3. Thyroid-sihulsting hormone lehzls in patients with 
atrial fibniladon and unexplained fieart fai?crc 
4. Cilebt radiograph and ECG 
5. Transthoracic Boppier-ho dimensioaal echocardiogra- 
phq' 
6. Noninvasive stress testing to detect ischemia in patients 
without angina but with a high probabilit>~ of coronary artery 
diseasc who wou!d be candidates for rekascularization 
7. Koninvasive testing to detect ischemia and assess myo- 
cardial hiability or coronary arteriography in patiears with a 
previous infarction but with no angina who would be candj- 
aaies for re\ ascularization 
8. Cardiac catheterlzationlcoronary ar:eriography in pa- 
tients with angina or large areas of ischemic or hibernating 
myocardium; also in patients at risk for coronary artery disease 
who are to undergo surgical correction of noncoronary cardlac 
lesions 
Class PI 
1. Semm iron and ferritin 
2, Yoninvasive stress testing to detect ischemia in all 
pt ients c \~ th  ~inexgiained heart failure who are potential 
candidates for revascularization 
3. Coronary arteriography In a11 patients with unexplained 
heart failure who are potential candidates for revascularization 
4. Endomjocard~ai biopsy in patients a') uith recent onset of 
rapidly deteriorating cardiac fucction or other ciinlcai ~ndlca- 
lions of myocardiris; b) rcceivlng chemotherapy with adnamy- - 
a n  or similar myocardial toxic agents; c )  wirh a sj~temic 
disease and possibii: cardlac invol~ement (hemochromatosis, 
sarcoid, am~ioid, LoeBer's endocardieis, endomqocardia! fi- . 
Sroelaaosis 
5. Thyroid-stinulating hormone levels m patients wlrk si- 
nus rhythm and dnexplamed heart failure 
Class PI1 
1. Repeat csrd~ac catheterizationlcoronaly arteriography 
or stress tes~ing in patients in whom coronasy arieq disedse as 
a causz of left ventricular dysfunction hac been excluded 
JACC Vol. 26, No. 5 
November 1, lt795:1376-98 
previously and no objective evidence of intercurrent ischemia 
or infarction has occurred 
2. Endomyocardial biopsy in the ~outlne evaluation of 
patients with chronic heari failure 
3. Multiple echocardiographic or radionuciide studies in the 
routine follow-up of patients with heart failure responding to 
therapy 
4. Routine Holter monitoring or signal-averaged electro- 
cardiography 
5 .  Cardiac catheterizationlcorona;" arteriography in pa- 
tients who are not candidates for revascularization, valve 
surgery or heart transplantation 
Diastolic QysJfunction: Evaluation 
Tbe majoriy of patients presenting with heart failure have 
reduczd ?eft vcntricu!ar systolic function and variable degrees 
of diastolic dysfunction. However, a significant subset (30% in 
some series) hzve norrnai or near-normal rest systolic hnction 
and predominantly diastolic dysfunction. The managernen? of 
patients with prin~arily systolic or diastolic dysfundion is very 
different, and it is critical to make the distinction. A review of 
diastolic dysfunction has been published recently (33j. 
Diastolic dysfunction impairs ventricular filling by diminish- 
ing relaxation (during early diastole) or reducing compliance 
(early to late diastole) of the ventricle, or both. The hemody- 
namic consequences include elevation of ventricular filling. left 
atrial, pulmonary venous and pulmonary capillary pressures, 
I 
I and if uncorrected, an eventual increase in pulmonary artery 
and right heart pressures. The elevated filling pressure is 
frequently sufficient to maintain a normal stroke volume and 
cardiac output at rest, but the latter ohen are compromrsed in 
situa~ions that require an Increase in cardiac output (e.g., 
exercise). 
Mjocardlal ischemia, hypertrophy and fibrosis are the usual 
underlying pathologic processes for ventricular diastolic dys- 
function, and the most common etiologies include c a r o n q  
artery disease, systemic hypertension, diabetes rnellitus, aortic 
stenosis, hypertrophic cardionyopathy, infiltrative cardio- 
myopathies and endocardial fibroelastosis. Decreased ven- 
tricular compliance also occurs as part of the normal aging 
process. 
Clinical manifestatrons can range from no symptoms to 
dyspnea, pulmonary edema, signs of right heart failure and 
exercise m:o!erance. Whereas diastolic dysfunction usually 
presents as a chronic condition, acute diastolic dysfunction 
producing acute pulmonary edema is no: an uncommon man- 
. ifestation of acute myocardial ischzmia or uncontrolled hyper- 
tension. 
Diastolic dysfunction should be suspected when a patient 
presents with symptoms and signs of congestive heart failure 
and has normal or cear-normal vectricular sysrolic fi~nctloc. 
Dopp!er echocard~ography or radionuclide imaging is oi value 
in assessing systolic function and detecting diastolic dysfunc- 
tlon; the latter by measrrrlng indexeb of rbe rat: of drdstolic 
fillrng. 4lt~rnativeiy, cardiac catheterization mat be used and 
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may be of particular value when noninvasive studies are 
nondiagnostic. Unless another diagnosis has been established, 
most of these patients should be evaicazed for underlying 
coronary artery disease and myocardial iszhemia. Noninvasive 
testing to detect coronary artery disease may be used as in 
patients with sysroiic dys5~nctIon. ,4lternativeiy, one could 
proceed directly to cardiac cathzterizs;ion,'zoronary arteriog- 
raphy 1) when there is a high suspicion of occlusive coronary 
artery disease as the cause of the 3iastolic heart failure (e.g., 
presence of angina or previous ~ o c a r i i a l  infarction) and is 
potentialiy treatable hy revascularizaiion; 2) when the possi- 
bility of occlilsive coronary artery diszzse cannot be reliably or 
safely zssessed by other methods; arid 3) when a patient with 
two or more risk factors for coronaq; atherosclerosis is slated 
lo undergo cardiac surgeq for what is beiieved to be the 
primary cause of the diastolic heart failure (c.g., aortic steno- 
sisj. Conslrictivc pericarditis, a surgically treatahlc condition, 
must be excluded in patients tvhose diastolic dysfunction 
appears to be secondary to a ~esaictisc ~rdiomyoparhy; in rhis 
setting, echocardiography, computerized tomogrdphy or MRI 
or the finding of significant ~nyocardial pathology by endo- 
myocardial biopsy (e.g., myocardial arnyloidosis, hemockroma- 
tosis) can be very helpful in guiding management. 
Assessment of Neurohomonal Activity in 
Heart Failure 
A variety of endogenous neurohormonai systems are acti- 
vated in patients wizh chronic heart failure, and suck activation 
may play a role in the pathophysiology of the disease. Among 
the most important of these neurohorrnonal derangements is 
the acrivation of the sympathetic nervous system and the 
renin-angiotensin system. The sympathetic nervous system is 
activated early in the disease process, and its activity may be 
increased even in patients with aspptomatie left ventricrrlar 
dysfunction. The renin-angiotensin system appears to be acti- 
vared later in the discase process (once diuretic therapy has 
been initiated), and its activity is markedly enhanced in 
patients with advanced symptoms (particular$those with renal 
hypoperfusion). Other vasoconstrictor hormonal factors that 
appear to be increased in heart failure include enciarhelin and 
vasopressin. In addition ro the activation of the vasoconstrictor 
hormonal system, the activity of several hormonal systems with 
vasodi!ator activity is also altered in patients with chronic heart 
failure. 
Experimental and clinical observations suggest that neuro- 
hormonal activation plays an important i o l ~  in the develop- 
ment and progression of heart failure. These hormonal systems 
exert hemodynamic eBects thar can alter cardiac function; 
prolonged activation may also exerr direct deieicrious effects 
on cardiac muscle cells. Such actions have Led to the deveiop- 
ment of therapeutic interventions designed to block the effects 
of endogenous vasoconstrictor systems as well as enhance the 
eifects of endogenous vasodilator systems. The clinical utility 
of many of these interventions (2.5, angioiensin converting- 
enzyme inhibitors and beta-adrenergic blackting agents in 
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selzcred patients) is well established, whereas the eEcacy of 
others (e.g., vasopressin antagonists and endothelin antago- 
nists) is still under investigation. 
Despite their pathophysiologic and therapeutic importance, 
there is littie reason to measure ci~;ulating hormonal facrors 
in patients with heart failure to guide routine clinicaI care. 
,Mthough such measureme~ts are useful in the setting of a 
research study, there is little evidence that such measurements 
assist in the routine assessment and management of parien:~. 
Furthermore, such measurements have not been shown to 
guide the rational selection of a specific therapeutic interven- 
tion in patients with heart Mure .  
Class 11 
1. Exercise testing to more definitively assess functional 
capacity and symptomatic iirnitaticr,~ in patients in whon a 
disparity exists between sy~p toms  expressed and clinical as- 
sessment 
2. Exercise testing to address speci6c ciiriicai questions and 
issues. Exzrnpies inciude vecrricnlar rare changes and control 
during atrial fibrillation or after pacemaker placemeat, blood 
pressure control in a patient with heart failure wilh a history of 
hypertension, exercise-induced arrhythmias, quantittitive eval- 
uation of degree of disability and zssessing a change jn 
functionai capacity or response to therapy 
Class III 
Exercise testiag as s roatice, serial$ pe&rmed procediire Assessment of Functional Capacit?, to foijow chronic venrricaia~ djsfill-:ctiofi that is cliriicaily s:zble 
Assessment of functional capaciry in patients with conges- ilxiess to assess candidacqr for t;-af.,splantatlon 
live heart failure 1s important, for functional capacity has a 
direct impact on patien; weii-being and quaiiy of life. Im- 
provement of functional capacity is therefere a najor goat of Summary 
therapy in patients with heart failure. ,Also, tdnctioaal capacity 
is a predictor of mortality in patients with heart failure, even 
after controlling far the prognostic information contained in 
various laboratory tests. Risk assessment of patients is essential 
to the choice of therapy, particularly surgicai approaches. 
Functional assessment of the patien? encompasses several 
dimensions, including physical capacity, emotional status, co- 
cia1 function and cognitive capabilities. Assessment of physical 
function is most important, but the other dimensions are also 
relevant. Emotional, social and cognitive factors nali  have a 
strong effect on the patient's capacity to adhere or respond to 
a therapeutic regimen and may be adversely affected by the 
underlying disease or its treatment. Clinical assessment of 
these dimensions, especially depression, social support and 
cognitive capabiliry, should be performed regularly. The esrab- 
iished standard for assessment of physical capacity is the 
exercise test, particularly measurements of exercise time or 
distance, peak work load and maximal oxygen consumption. 
These measures' can be assessed using a treadmill excrcise test 
and have the advantage of objectivity. However, these tests are 
relatively expensilc and carry a small risk. 
Inquiring about the patient's tolerance for comnlon daily 
activities can proiide an alternative method for assessment of 
functional capacity. Because patients may gradually restrict 
their activhies to avoid sympto~s,  it is preferabie to inquire 
about tolerance for weli defined activities (e.g., walking 100 ft 
[90 mj on level ground, climbing one or hto flight\ of stairs). 
Recommendations for Assessment of Functional 
Cclpnctp in Heart Failure 
Class I 
i. Patient interview or questionnaire at each clinic visit 
2. Exercise resting, usually with respiratory gas analysis, to 
determine potentiai candidaqr for k a r t  transplarrration 
Patients presenting with chronic heart failure an3 those 
patients with acute hear: failure in whom the cause was not 
established during the stabilizailon period should undergo 
diagnostic testing to determine the etiology. 
Hear: failure due to diastolic djcfi~nction must be differen- 
tiated from that due to systolic dysfunction. This can be done 
by transthoracic Doppler-two dimecrional echocardiogra- 
phy, radionuclide imaging or cardiac catheterization. 
Coronary artew disease must be excluded as the causai 
factor in patients withheart failure. 
Patients with angina shou!d undergo cardiac catheterization 
and coronary arteriography if they are otl-renvise candidates 
for intenrenrional procedures. 
Opinion is divided as to the proper approach to patients with 
known corona9 ar teq  disease and heart failure but itithout 
angina. Either coronary arteriographj or noninvasive testing 
with coronary arteriography lrmited lo patients demonstrat- 
mg ischemia or hibernating rxyocardiun~ mxy be considered. 
The approach to orher patients wifh heart failure will 
depend in great part on the probability of coronary arrery 
diser~se as the cailse of k a r t  failure. For patients with a high 
probability, such as those with multiple risk facars, a no rc  
aggressive diagnostic approach may be isdicated, whereas in 
patlents wi:h a Ion probability, neirher coronary angiogra- 
phy nor stress testing may 52 necessary. 
hfjocarditia is a rare muse of rapidly progressive heart 
failure and requires myocardial biopsy to establish the 
diagcosis; there is no evidence that immunosuppressive 
therapy is beneficizi 
Measurexeni of crrculating neurohorxone Ieveis is of little 
value in the routine assescment and rnsnsgernenr of 2af:ents 
with heart failure 
Ongoing assessment of filnctional capdclty plays an impor- 
tant role in tne nanagernent of patients w:lh r?e;rl failure 
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and should include physical capacity, emotional status, social 
functior, and cognitive abilities 
Systolic Dysfi~nction: Therapy 
r T  
r hz trehtrneat of Qronk heart failare ha> changed remark- 
ably in ihi: past 10 to 1 years. Heart failure is no l o ~ g e r  
considered a simple edematous s.;ate that .s respitnsive to 
intermittent diuretic therapy. Many if not most patients are 
now noneJernatous, but the cc~ditiun is sill: disabling and 
lethal. Forrunztely, a number of important ciinical trials have 
led to substantial improvement 11: the :rea!meni of patients 
with New York Heart Associatior; functional class I to IV heert 
failure dbe to systolic dyslunction (22,36-41'). 
Functional class I. Patients with kactionai class I status 
have left ventricular systo:;c &yslunct~o~~ bil; manifest no or 
minimal overt slgns or sqrnpioms of heart falure. 114 many 
cases, patients in functional ciass I have previously been 
symptomatic with heart ia'a;Iure but have become well coxpen- 
sated despite residual left ventricular systolic dydunction. In 
other cases, patients ma? have sustained left ventricular dan- 
age as a result of myocardial infarction, onset of dilated 
cardiornyopath! or somc other progressive disease process 
conpromibing left ventricular systolic funct~on but remain 
asymptomatic or very mmimally symptomatic. 
Because patients in functional ciass I nlth left ventricular 
systohc dysfunction are asymptomatic or minimally sympto- 
matic, pharrnacologic therapy often is not prescribed. Nou- 
ever, angiotensin-converting enzyme (ACE) inhibitor therapy 
is appropriate for patients in +~nctionai class I as a means of 
preventing heart fallure (37) and may reduce mortality after 
- 
acute myocardial infarction (38). Tn the Studies of Left Ven- 
tricular Dysfuncrion (SOLVD) prevention trial (33, enalapril 
significantly reduced the incidence of heart failure and :he rate 
of related hospital admissions compared with that for placebo 
(371. In the Sdmival and Ven;ricular Enlargement (SAVE) 
trial (381, patients i+ith ejection fractions 3 . 4 0  but without 
overt heart failare or myocardial ischemia 3 to 16 days 
(average li days) after myocardial infarction derived a 19% 
overall reduction in the r~sk of death from all causes (p = 
0.019) !%hen treated with long-term captopril for an average of 
42 months. In the Gruppo iiaiiano per lo Studio deila Soprav- 
viema nell'lnfarto M~ocardico (61SSIj-141 (391 and Interna- 
tional Striiif of Infarct Survival (ISIS) IV (40) trials, oral ACE 
Inhibitor therap? begun within the first 24 h in pazients !*irh an 
acute mjocardlal infarchon bas also beneficial in patlenis with 
and without heart $allure. Hc\vever, the use of mtravenous 
enalaprilat in the firs1 24 n of an acute mfarczion followed b> 
oral eralapril ogered no s ~ h d  arivawage over placebo in 
the Coopeiatite New Scanciina~ian Enalaprii Survival Study 
(COKSENSCS) IT trial (411, and the use of intravenous ACE 
, 
~nhibitors after acute ryocarbiai idarct~o~s e not recorrtmended. 
On  hi basis of these studies, oral ACE ;chibiton sho~ld  be gAven 
to ail patients in f~~ilncflonal class I nilh s1gn:ficdii.t ! ~ f t  ~entricula; 
systohc dyshr.ct~or. (ejzct:on fraction (35% to 40% 1. 
Connraind~cations to 3 trial af ACE ~xhbltors include 
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shock, angioneurotic edema or significant hyperkalemia. 
Asymptomatic hypotension ji.e., systolic blood pressure 70 to 
90 rnm Fig) is not a contraindication to .ACE inhibitor therapy, 
but ciinical judgment must al;vays gcvzrn therapeutic deci- 
sions. Dosing is very important, and ?o-iirer doses should be 
used initially and gradually increased. Zxalapril shouid be 
started at 2.5 mg mice daily arid tirrated to 10 mg twice daily, 
whereas cap~opril shouid bc begun at 5.25 or 12.5 rng thrce 
times a day, alid gradually (over weeks) tkrated to 50 mg three 
times a day. The larger doses are those shown to be eEectisle in 
reducing mortality in large-scale studies. 
Because patients In fiinctiona? ciass 1 rarely retain fluid or 
become edematous, sodium restriction ar,d diuretic drugs may 
not be uniformly indicsted. Additionally, patients in funcrional 
class I may have pedal edema from a varie~jr of causes 
anrelated to hear: failure. %'her, a diuretic drug is necessary 
because of peripheral edema or mild jugular venous distension 
despite sodium restriction, nonloop diuretic drugs; such as 
kjdrochlorothiazide or chiorthalidone, may sufice. Overzeai- 
ous treatment with diuretic drugs may reduce plasma volume, 
cardiac output and blood pressure. thus stimulating neuroen- 
docrine activation (42-44). Therefore, for the patient in 
functional class 1, it is prudent to witkhold diuretic therapy 
unless there is clear evidence of salt and water retention 
despite a low sodium diet. 
Functional classes TI to TV. Reports of thc SOLVD (221, 
Veterans Administration Cooperative Vasodilator Heart Faii- 
ure Trial (V-Hem) 11 (35) and Cooperative North Scandina- 
vian Enalapril Survival Srudy COKSENSUS (36j trials support 
the use of ACE inhibitors in all patients with yjmptomatic 
heart failure, unless the inhibitors are contraindicated or not 
tolerated. If possible, the dose should gradually be increased to 
that shown to reduce mortality in these trials (i.e., 20 rng of 
enalapril or 150 mg of captopril daily). Lisinopril(5 to 20 rngiday) 
and quinapri (5 rng twice daily) havc aiso been approved for the 
treatment of heart failure. n e s e  latter drugs have been shorn to 
improve exercise tolerance and symptoms. In addition, in the 
Acute Infarction Raniprii Efficacy (AIRE) study (451, ramipril 
(5 mg hiice daily) aiso reduced mortality when begun befwveen 
3 and 10 days after an acute myocardial infarction in patients with 
heart failure. There are insugcient data regarding the effect of 
lower doses and alternative ACE inhibitors on mortality in 
palienis with heart fadure. Once a patient has begun ,4CE 
inhibitor therapy, the drug should be prescribed for an indefinite 
period of time, probably for iife if well tolerated. 
Data from V-HeFT I (34) and I1 (35) established a rolc for 
isosorbide dinitrate and hqdralazins for patients with func- 
tional class II and III heart failure. Although ACE inhibitors 
are the cornerstone of treatment for heart failure, isosorbide 
dinitrate and hydralazine shoiild be considered when ACE 
inhibitors are not tolerated because of symptomatic hypoten- 
sion, azoternia, hyperkalenia, coegl-i, rash or angioneurotic 
edzrna. Isosorbide dinirrate (5 to 10 rng three times a day) and 
hydralazine (10 rng four times a day) should be ihe initial 
doses. If tolerated, hydralazine should be increased gradually 
to 75 rng four rimes a day and isosorbicle dinitrate to 4G mg 
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three times a day. A minimal 10-h "nitrate-free" period at 
night usually should be achieved to avoid nitrate tolerance. 
Occasionailg, hgdraiazine and isosorbide dinitrate arc added to 
an ACE inhibitor when symptoms of dyspnea or fatigue 
persist, but data to support this comhination are scanty. 
Patients with symptomatic heart faiiure are more iike1.1 to 
retain sodium, and a diuretic drug asaally is indicated (46). 
Initiating diuretic therapy is highly individualized. Many phy- 
sicians begin with a tkiazide diuretic dmg, but reduced renal 
perfusion may ultimately favor the use of a loop diuretlc such 
as furosemide or bumeranide. Thiazide diuretic drugs are of 
less valne if the gjomerdar filtration rate (GFR) is <30 to 
40 mllmin and may actually reduce this rate furrher. Patients 
should be advised to weigh themselves daily and keep a log of 
their weight. An increase of 1 or 2 kg may be an indication to 
supplement the maintenance diuretic dose. For example, 
2.5 mg of metolazone may be added for 2 or 3 days to the loop 
diuretic drug, followed by a return to the usual maincenanre 
dose o-t' ioop diuretic drug when the weight stabilizes. 
Eliminating the salt shaker at the table, salt in the cooking 
and the institution of a iotv sodium diet shouid be introduced 
progressively into the therapeutic program, depending on the 
clinical cirmstances. Sodium restriction becomes a critical 
strategy in the treatment of heart failure as the disorder 
progresses, and its importance cannot be overstated. Sodium 
intake should be limited to 5 2  g/day before one resorts to large 
doses or multiple diuretic drugs. 
When diuretic drug resistance develops, using a combina- 
tion of diuretic drugs that act in different nephron segments 
(i.e., thiazide or metolazone plus a loop diuretic drug) is often 
effective (47,481. Severe electrolyte and volume depletion can 
occur when metolazone is combined wirh a loop diuretic drug 
(481, and hospital admission may be warranted in some 
circumstances ji.e., in the presence of hypotension, azotemia, 
oliguria or asciles). Careful patient and laboratory monitoring 
is necessary when these diuretic drugs are combined. An 
increase in BUN, particularly when disproporrionat- to serum 
creaiinine levels, is usually corrected by reducing the diuretic 
dose and is not necessarily an indication to reduce or stop the 
ACE inhibitor. Under most circumstances, a miid increase in 
BUY or serum creaticine Ieveb is well tolerated without 
discontinuation of the diuretic drug or ACE inhibitor. Patients 
with truly refractory or resistant sodium retention and heart 
failure may require hospital admission to receive intravenous 
dobutarnine (2 to 5 &kg body weigh1 per min), dopamine (I 
to 3 pdkg per minj or a constant in-filsion of furosewide (1 to 
5 mg'h). Fluid restriction to 1,000 to 2,000 milday is of value in 
patients with dilutional hyponatremia. 
Hypokaiemia and contraction alkalosis are frequent accom- 
paniments of vigorous diuretic drug use. Because ventricular 
arrhythmias occur in ine majority of patients with heart failure 
2nd arc aggravated by hypokalemia, potassium must be re- 
placed or hypokalemia prevented. Potassium chloride is fre- 
quently required in doses of 20 to 60 rnEqiday to maintain 
serum potassium in the 4.5- to 5.0-rnEq,'iifer range. Dietary 
suppiemenration of poiassi~im is rarely wficienz. Ai~ernaliveiy, 
potassium-sparing agents, such as arniloride, lriarntereee or 
spironoiactone, can be used to maintain su5;ient serum 
potassiun, leveis. Dangerous hyperkalernia may occiir when 
ACE inhibitors are used in combination with potassium- 
sparing agents or large doses of oral potassium, and serum 
potassium levels must be caref111iy monitored. Fqpefkdernia 
and sodium rerenrion are particularly common when nonste- 
roiJai anti-inflammatory agents are used in patients with 
severe heart failure. In general, nonsteroidd mti-it-dannutory 
agents should be avoided in patients with heart failare. Hypomag- 
nesernia (serum magnesium leve"il.6 mEq1liter) should aiso be 
corrected when obsenred. 
Digitalis giycosides have been used for >2ii0 years to treat 
heart failure, yet controversy still persists regarding their use in 
patients wirh hearr failure and normal sinus rl.,yrhm (49). The 
role of digoxin in patie~~ts ivitk heart failure and atrial fibril- 
lation is accepted, and recent studies (50-52) indicate that it is 
an effective therapeutic agent in many patients with symptom- 
atic left ventricular systolic dysfunction and sinus rhythm. in 
double-blind placebo controlled trials, digoxin has been shown 
ro incrcase left ventricular ejection fraction (53) and exercise 
tolerance (54) in patients with chronic heart failure. It may also 
reduce sympati~etic activity as a major mechanism of action 
j55j. Patients receiving long-term digoxin therdpy with (56) or 
without (57) concomitant ACE inhibitor therapy may manifest 
clinical deterioration when digoxin is withdrawn. Digoxin has 
not been shown to be efficacious in asymptomatic patients with 
ventricular systolic dysfunction. Uncertainty regarding the use 
of digoxin derives primarily from the lack of data regarding its 
effect on mortality. To remedy this uncertain?{, ihc National 
Heart, Lung, and Blood institute and the Department of 
Veterans Affairs are currently conducring a iarge placebo- 
controlled clinical trial (DIG-Digitalis Investigator Group). 
This srudy of the effect of digoxin on survival in heart failure is 
scheduled to report its results in 1996. Until the results of the 
trial are released, controversy will persist regarding the appro- 
priate role of digoxin in patients with heart failure who are in 
sinus rhythm. 
Calcium channel blocking agents are sometimes used as 
antianginai therapy or antihypertensive agents in patients with 
angina or hypertension who hate left ventricldar dysfuiic:ion, 
but they may worsen heart failure (58-60). The risk of 
worsening heart failure aiso appears to accompany the use of 
newer agents in this class (e.g., feiodipine [iilj). As a result, 
physicians should not consider calcium channel blockers as 
safe or eilective agents in the treatment of chronic heart 
failure. However, in the Prospective Randomized hlodipine 
Surgival Evaluation (PRAISE) trial (presented ar the 34th 
Annual Scientific Session of the ACCJ, the administration of 
amiodiplne in patients with heart failure was nor accompanied 
by an adverse efFect on morbidity or mortality; rather, the study 
reported a favorable effect of amlodipine on the sunivd of 
patiefits with nonischemic dilated cardionyopathy. This pre- 
liminary finding is being further evaluatzd in a follow-up trial. 
Therc has been considerable interest in thc use of bera- 
adrenergic blocking agents in the treatment of chronic heart 
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failare since early reports from Sweden (62) first suggested the 
possible usefulness of metoprolo1 in paiients with dilared 
cardionyopathy. Metopralo! wis reporned (62,631 to 3ave 
beneficial clinical and hernodynamic efFec:s, whereas with- 
drawal of the Srug whs associated with symptomatic deterio- 
ration. However, these studies were uncontroiled and, thus, 
d i f ic~i t  o icterprel. Small, controlled clinical smdies (itsualiy 
of short duration) produced coni3ceing results (64-66). 
More recently, beta-blockers witk addi'ional pkarrnacologc 
properties have been evaluated extensively in long-term place- 
bo-controlled clinical trisls of patients with chronic heart 
failure. Seblvoioi and bucindolol, which have both heta- 
blocking activity and vasodilator properties, improve left ven- 
tricular performance during long-term therapy (67-59). Carve- 
diiol, which also has combined beta-b!ocker and vasodilator 
activity, has been shown in several placebo-controlled studies 
to (70-72) improve left ventricular hnctiox, symptoms and 
submaximal exercise tolerance In patients with s~7mptc;ms of 
wide-ranging severity. 
In addition, several trials have silggested that long-term 
beta-blockade may reduce morbidity and mortality in patients 
with chronic heari failure. Beta-blockers have been shown (73) 
to reduce mortality in high risk patients after an acute myo- 
cardial infarction, including many patients with heart ' ~ a l  '1 ure. 
The Metoproloi in Dilated Cardiomyopathy (MDC) trial (74) 
demonstrated that rnetoproiol reduces the combined risk of 
mortality and the need for heart transglantatio~. in patients 
with idiopathic dilated cardiomyopathy. The Cardiac TnsuG- 
clency Bisoproloi Srudy (CIBIS) (75) showed a significant 
reduction in hospital adminssions for heart failure and a 
nonsignificant decrease in mortality, but the trial was too small 
to evaluate the effect of the drug on sunrival. Reportedly; 
carvediioi has been shown (76) to reduce mortaliq in a 
large-scale clinical trial program conducted in the United 
States that enrolled >1,000 patients. In that trial, the beneficial 
effect on mortality was seen in patients with functional class 11 
and class 111 or IV symptoms as well as in patients with and 
without coronary- artery disease. This eEect also was accompa- 
nied by a significant dzcrcasr in the risk of hospital admissions 
for cardiovascular causes. Additional survival trials with beta- 
blockers are being planned or are in progress. 
At the present time, <he use of beta-blockers for the 
treatment of chronic heart failure remains investigational, but 
the oficial status of beta-blockers may change as recent data 
are revie\qred. Hence, physicians might consider the use of a 
beta-blocker in selected patients with chronic heari failure. 
However, this approach shoiiid be taken only with consider- 
able caution because the initiation of beta-blockade may 
exacerbate heart faillire in some patients (72,75). 
Anticoagulation with warfarin is frequently used for pa- 
tients with chronic heart faiiure to prevent systemic emboliza- 
ton .  This practice is based largely on retrospective analyses of 
referral populations (77). Is V-HeFT 11 (78) there were only 
46 clinical ernbolic events in 866 patients (5.7%) followed up 
For an average of 2.6 yzars. In the SOLVD trial (79j, only 5.3% 
of patients experienced a ciii~icai embolism during 39.2 months 
of follow-up. In an analysis of tke majar studies (801, the 
incidence of arterial thromboemboiism ranged from 0.9 to 5.5 
cvsars!100 patient-years, with tiiz :argest studies reporril~g an 
incidence of 2.0% and 2.4%1/110i? patients-years. However, 
clinical ernbolic conpiications were !inked to i: low ejection 
fraction (77,78), and many physiciri~is currently administer 
anricoag~lation :o patients with an cjmion fraction <20% to 
25%. Similarly, many physicians will administer anticoagula- 
tion in patients with lefi ventricular dpsfmnc~ion and an i ~ t r a -  
cardiac thrombus. However, the vaiue of this approach is 
unciear, except in patients with thrixribus after an acute 
infarction. Patienis with arrial iibriilation should receive anti- 
coagulation to achieve a target range of international normal- 
ized ratio of 2.0 to 3.0 (81). ,4 recenl rcport (52)  suggests that 
the optimal range of anticoagulation for patients with a 
documented embolism should be 2.8 to 3.9. There are no 
controlled trials demonstrating the eEcacy of routine antico- 
agulation in other paticnts with heart faiiure and normal sinus 
r?iyyrhm, and its use here is questionable. 
Patients with heart failure and atrial fibrillation should have 
their ventrimlar rate controlled. Multiple dmgs may be nec- 
essary, such as digoxin, diltiazem or a beta-blocker. Uncon- 
trolled or nevt-onset atrial fibrillatior.: can worsen heart failure 
or lead to decompensation. It is usually prudent ro convert 
new-onset atrial fibrillation or atrial fi'nriilation of uncertain 
duration to normal sinus rhythm. in  some cases amiodarone or 
occasionally catheter ablation or modification of the ,4\1 node 
may be necessary to prevent uncontrolled, rapid ventricular 
rates. 
Ventricular arrhythmias are nearly omnipresent in patients 
with heart failure (83,84). Asymptomatic ventricular arrhyth- 
mias (including mild palpitations and aonsustained ventricular 
tachycardia) should not be treated becmse there currently are 
no data to support this stratear (85).  heiarrhythrnic therapy 
can worsen ventricular arrhythmias and produce negative 
inotiopic e8;ects in patients with heart faiiure (86-88). Routine 
Holrer monitoring and signal-ave:aged electrocardiography 
are not indicated but may be useful in patients withsyi-np- 
i o n s  suggestive of arrhythmias. Patients with symptoms due 
to ventricuiar arrhythmias: bradyarrhy~hrnias ilr cardiac 
syncope (89,901 (inc!udi:~g those who survive a cardiac 
arrest) should be referred to a cardiac specialist for f-iirther 
evaluation. 
When antiarrhythmic drugs are used in parients with heart 
faiiure, they ordinarily should be initiated in the hi?spi?al, 
Empiric use of type I antiarrhythmic drugs should be avoided 
for treatment of ventricular arrhythmias in patients witk heari 
failure. There are several large clinical trisls currenrly under- 
way that are designed ro assess the role of amiodarone and 
cardio1~errer-defibri11ator devices as therapy for this irnportar~t 
and complex problem. The recently completed Grupo de 
Estudio de fa Sobrevida en la Insuficiericia Cardiaca en 
Argenrina (GESICAj trial (31) demonstrated an improvement 
in sunivai in patients with heart failure randornizd to receive 
arniodarone. In contrast, the Sunival Trlai of i%ntiarrk~$hmic 
Therapy in Congestive Heart Failure (92) reported no im- 
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provernent in survival nor a reduction in sudden deaths in 
patients wirh heart failure and asymptomatic ventricular ar- 
rhythmias treated with amiodaronz. However, there was a 
t ~ e n d  toward improved survival in patients with nonischemic 
cardiomyopathy (92). Therefore, the empiric rise of amioda- 
rone for patients with heart faiiure needs e~r ther  study. 
Vv'hcn pazienrs with chronic heart failure become refractory 
to iherapy, hospital admission is uslialiy indicated. This ap- 
proazh is pzrricuiarly useful when symptoms arc progressive, 
and large doses of oral djuretic drugs no longer achieve 
adequate diuresis. Short periods of bed rest alone may produce 
diuresis. A change from oral to intravenous diuretic drugs may 
also be usefuul (93). The use of dobutamine or phospho- 
diesterase inhibitors to temporarily improve cardiac output 
and renal blood flow is sometimes effective in lessening 
symptoms and relieving refractory salt and water retention. 
Low dose dohulamine (2 to 5 #&kg per min) is frequently 
suflicisnt,, whereas larger doses of dobutamine may produce 
tachycardia, ventricular arrhythmias, hypokaiemia and myo- 
cardial ischemia. Alternatively, intravenous milrinone 
(50-pg,/kg loading dose, then 0.375 to U.75 pg/kg per min) may 
be used. Occasionaily, patients may improve symptomatically 
as a resuit of long-term low dose dobutamine infusion (2 to 5 
pgjkg per min) given through an indwelling central catheter on 
a long-term outpatienr basis (94). Continuous outpatient ther- 
apy, with gradual weaning, is most useful in patients who 
cannot be weaned from inotropic therapy as an inpatient. 
Intermittent outpatient (or inpatient) therapy for 12 to 24 h at 
intervals is useful in patients who require repeated hospital 
adinissioi~s or emergency department visits for therapy of 
volume overload or symptoms of low cardiac output. However, 
rhc value of long-term low dose inotropic support in an 
outpatient setting remains uncertain. Furrhemore, concerns 
have been raised about its safety in light of the increase in 
mortality reported with high dose outpatient dobutamine 
infusions (45) and long-term miirinone therapy (96). 
Phamncologic Treatment of l e f t  Ventricular 
Sy.vtolic @sfunction 
Class I 
1. .4CE inhibitors for ail patients with significantly reduced 
!eft ventricular ejection fraction unless contraindicated 
2. Hydraiazine and isosorbide dinitrate in patients who 
cannot take ACE inhibitors 
3. Digoxin in patients wirh hear: failure due to systolic 
dysf~rnctiun not adequately responsive to ACE inhibitors and 
diurctic drugs 
4. Digoxin in patients with atrial fibrillation and rapid 
ventricular rates 
5. IPiure-~ic drugs for patients with Auid overload 
6. h;icoagulation in patients with asrial fibrillation, or a 
previous history of systemic or pulmonary embolism 
7. Beta-blockers for high risk patients after ail acute myo- 
cardial infarction 
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Class I1 
1. Digoxin for ail patients wirh heart faiiurz due to left 
ventricular systolic dysfunction 
2. Addition of hydralazine and isosorbide dinitrate for 
patients ivho do no?; respond adequately to ACE inhibitors 
3. Beta-blockers for patlznrs with dilated c~rdiornyopathy 
4. Anticoaguladon in patients in sinus rhyrbir, with i ire? 
low ejection fraction or intracardiac thrombi 
5. Outparient 10xv dose dobutamine infusion for refractory 
heart failure 
Class IH 
1. Calcium channel blockers in tke absence of coexistent 
angina or kype~teasion 
2. Trearmznr of asyrnprornar;~ ventricular arrhythmias 
Heart transplantation should be coasidercd in patients with 
heart failure refractory to medical or surgica; therapy. The 
reader is referred to two recent reports (97-98) rcgarding 
the role of transplantation in the treatment of hearr failure. 
Other surgical procedures, such as cardiomyoplasty, and the 
use of mechanical ventricular assist devices remain investi- 
gationai. 
Intense physical exertion should be discouraged, but mod- 
erate exercise to tolerance should be strongly encouraged. 
Mild to moderate dynamic exercise, such as walking or recre- 
ational bike riding, is preferred. Isometric exercise (i.e., work 
against gravity), such as push-ups or weight Iihing, should be 
discouraged because it presents an acute afterload stress to :he 
left ventriclc. Rewiction of activity results in skeletal muscle 
decondition~ng, which can contribute to the fatigue associated 
with heart failure. With a physical conditioning program it is 
possible to increase blood Aow to exercising muscles (991, delay 
anaerobic threshold (10"J) and improve autonomic function (101). 
Diastolic &sfinction: Therapy 
Thz treatment of heart failure due to diastolic dysfunction 
has both similarities and dissimilarities to the treatment of 
heart failure due to sysroIic dysfunction. Our recommenda- 
tions do not include therapy for hypertrophic cardionyopathy 
because the pathophysiologic features and therapy for hyper- 
trophic cardiomyopathy d i k r  significantly from most other 
causes of diastolic dysfunction. Certainly, causal or aggravating 
conditions should be corrected if posslble (e.g., revasculariza- 
tion for coronaq artery disease, control of sqstemic h~perten- 
sion). Similarly, recornmenddrions regarding the use of antico- 
aglllation and anliarrhlthmic agcnts and the rolz of activity 
apply to both conditions. However, there are important differ- 
ences in :he pharmacoiogic approach to bystolic and diastolic 
dysf~~ncrion. The goal of drug therapy in diastolic dysFuncrion 
is to reduce symptoms by lowering the elevatcJ filling pres- 
sures without significantly reducing cardiac ourput. Th:s goal 
can be accompiisheii 54 the judicious ~lse of diuretic drugs and 
nrtrates. Because 31-1 adequate cardiac outpct dcprnds on the 
elzvated Ming pressure, such patients are prone to develop 
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hypotension, and small doses of diuretic drugs or nitraies 
should be given initially, with careful monitoring to avoid 
adverse effects. Calcium ckznnel anci beta-blockers have been 
proposed to di;ecely Improve diastolic dysfunction by hugment- 
ing ventricular relaxatio~ or improiing cornpliancc: hut there 
are few data to indicate that these agents exert a cliriicaiiy 
Important effect by this mechanism sf acrioa. Bera-blockers 
may improve diastolic filling by reducing heart rate. ACE 
inhibitors are frequently used, but studies demonstraring 
their eifectii.ness in patients with diastolic function are 
limited. 
Because systolic hnction is generally normal or near nor- 
mal, positive inotropic agents are of little use. As the disease 
progresses, systoIic dysfunction may develop, which should 
then be treated accordingly. Patients with diastolic dysfanction 
that is refractory to optimal medicaiisurgicai management 
shouid be evaluated for heart rransplantaiion. 
Phamacologl'c Treatment of t e j t  Ventricular 
Diastolic @S function 
Class I 
1. Diuretic drugs 
2. Nitrates 
3. Drugs suppressing AV conduction to control ventricblar 
rate in patients with atrial fibriltation 
4. Anticoagulation in patients with atrial fibrillation or 
previous systemic or pulmonary embolizaiion 
Class II 
1. Catcium channel blockers 
2. Beta-blockers 
3. ACE inhibirors 
4. Anticoagulation in patiznts with intracardiac thrombus 
Class III 
4.  Drugs with positive inotropic effect in the absence of 
systolic dysfunction 
2. Treatment of asymptomatic arrhythmias 
General Measures 
There are certain general measures that apply to all pa- 
tients with heart failure. Factors aggrrivatmg or precipitating 
heart failure shoilla be corrected (e.g., anemia, infections, 
hypertenion, obeslry). Alcohol can produce cardlomyopatky, 
and excessive intake can cause hqperte~~sion. Resiricrion of 
intake or abstinence should bc encouraged. 
The proper education of patients and their ramilies is 
imperative. Failure of patients to comply with their physician's 
~n~tructions 1 a frequenr cause of recurrent heart failure. 
Many factors produce thl? falure to comply, bur, unfortu- 
nakly, the patient's lack of underbtanilmg is a signlficanl cause. 
It i~ incumbent on physicians to be czrnin that patients and 
therr famll~es hake an undersraiiding of the causes of heart 
failure, prognosis, rherLip), d~ct'iry rzstrlct~ons, activity, irnpdr- 
tance of cornpilance <in2 the slgns a n ~ l  symptoms of recurrent 
heart failure. Home monitoring by other health care providers 
is of value if adequate support cannot oebenyise be provided. 
in addition. patients s h u l d  he strongly encouraged to con- 
srract written advance dirccrives for their future care. The 
instrucrion of family members In zardiopuin~onary resuscita- 
:ion should he ;ecommended. 
Systolic Dysfunction: Therapy 
e Ail patients with symptonatic heart failure and those in 
functional class I with significantly reduced left vemricular 
hnction should be treated wirh ax ACE inhiknitor, unless 
contraindicared or nor tolerated. 
s ACE inhibitors should be continued indefinireiy. 
s Thc recommended dose of ACE inhibitors for heart failure 
are the larger doses used in the c!inicai trials demonstrating 
improvement in survival. 
Patients with sympton~aiic hcarr failure should be trcaied 
with a diuretic drug, even when rendered frec of edema. 
Diuretic drugs should be used in conjunction wirh an ACE 
inhibitor. The dose and .type of diuretic drug may change 
according to fluid status but generally will be needed indef- 
initely. 
o Sodium restriction is a critical strategy in the treatment of 
patients with heart failure. 
e Calcium channel blockers are not of proven benefit for 
patients with systolic heart failure and may bz harmful. Such 
risks may not accompany the use of amlodipine, which is 
undergoing further evaluation. 
s Digoxin is an effective treatment in many patients with 
moderate to severe heart failure, but there is uncertainty 
regarding its influence on mortality. 
e Asymptomatic arrhythmias should not be treated in patients 
with heart failure. 
e The results with beta-blockers for the treatment of heart 
failure are encouraging, but their use remains investigational 
pending fi~il review of the available data. However, beta- 
blockers arc indicated (if tolerated) in the treatment of high 
risk patients after an acute myocardial infarction. 
Anticoagulation is indicated for patients with atrial fibrilla- 
lion or previous embolization and is frequently administered 
in patients with a very low ejection fraction or intracardiac 
thrombus. However, there are few data to support its routine 
use for hearr failure. 
o Low dose dobutamine or miirinone infusion may benefit 
selccted patients with refractory hearr failiiure. The infusion 
of low dose dobutamine on an ourpatient basis may rreuit in 
symptomatic improvement, but studies are needed ro deter- 
n~inc the eifect on sunrival. 
e Dynamic exercise as tolerated should be encouraged. 
Diastolic Dysfunction: Therapy 
e The goal of drug therapy in pxlents w i n  diastolic dysfunc- 
tion is to control symptorns bq reducing tenrricuix filling 
pressure without reducing cardiac output. 
1392 ACCIAIlA TASK FORCE 
HEART FAILURE GUIDELIKES 
JACC Vol. 26, ho. 5 
Novernoe: .. 1995:13'6-98 
e Diuretic drugs and nitrates are the drugs of choice for 
symptomatic patients. 
r Caiclum channel bl~ckers, 3eta-blockers and ACE inhibitors 
may be of benefit. 
e Agec:s with positive inotropic actions are not indicated if 
systolic mnclion is normal. 
Recommendations fir Hospital Admission of 
Patients With H e a ~  Failure 
Class I 
1. Patients experiencing moderate to severe heart failure 
for the first time 
2. Patients with recurrent hear? failure complicated by 
acutely threaten~ng events or ciinlcal situations (e.g., recent 
myocardial ischernialinfarction. acute pulmonary edema, hy- 
potension, pulmonary or systemic embolus, symptomatic ar- 
rhythmias or ot?ler severe medical ~Ilcesses) 
Class HI 
1. Mild to moderate decompensarion of chronic heart 
failure 
2. Patients experiencing mild heart failure for the first time 
Heart Failure in the Fetus, Infant and Child 
Children \nth heart failure differ from adults in two major 
ways: 1) There are maturational differences in contractile 
function, with improvement from early fetal gestation to the 
adult, making perturbation of the cardiovascular sqsrem more 
likely to have an effect on an immature subject. 2) There are 
congenital, structural and genetic causes for heart failure in the 
fetus, infant and child that are either modified by adulthood or 
lead to early death such that the causes of heart failure in 
infancy are largely due to congenital heart disease, ~vhzreas 
this is not the case in the adult. 
The term heart failure In pediatrics has the same definition 
as in adult cardiology, with many similar causes, some with 
reduced myocardial function. However, the most common 
cause of "heart failure" in infants and children is ventricular 
septa! defect, in which myocardial function is frequently 
normal. Therefore, in young patients with heart failure the 
systemic output is most often normal, but escessibe preload, 
afterload or pulmonary blood flow leads to pulmonary 
eJema. 
The rnajori9 of infants with heart failure have a surgicaily 
correctable cause, and surgical correction is a cjass 1 indication 
for treatment of such patients. The major consideration in 
these patients is the timing of operation, especially for those in 
whom the defect may become smaller (e.g., ventricular septa1 
defect). However, for medical management of heart failure in 
children. there are no long-term prospective, randomized, 
double-blind, placebo-control!ed or~tcomes data available. Es- 
sentially e\eny form of treatment has either been proposed as 
successfi!l or unsuzcessf~ll or, the basis of uncontrolied trials. 
Therefore, it is not possible at present to assign rrearrnent 
options clearly to class I or 111. It is hoped rkar rhe present 
document will stimulate formal outcomes ~esezrch in the fetus, 
infant and child to determine cptinal xan~gcrnen: 
Because the management principles of hear? failure in 
children acd ad& are gsne;ail:, hirnila:, only the major 
difference? irom those outiiced eariier in :his document will be 
presented in this sectior,, beginnmg wit2 acute k a r t  failure 
and continu~ng itlth the five common presentations of cl~ronic 
heart failure. 
Acute Heal? Failure 
The infant or child with heart failure is generally tachy- 
pneic, with a respiratory rate (taken while asleep) greater than 
-50 hreathslmin at < 2  years old and >40 breaths'min at 2 2  
years old. The iachypnea generally is uniabored and requires 
close inspection because the infant may appear to be comfort- 
able. The presence of retractions may indicate associated 
pulmonary infection or impending cardiovascular collapse. 
There is usually accompanying sinus tachycardia. Hepatomeg- 
aly is usually present, whereas splenomegaly is not. The patient 
may be diaphoretic and, depending on the state of the circu- 
lation, mottled in the presence of impending circulatory coi- 
lapse. Such infants may be diagnosed incorrectly as having 
sepsis. The pulse volume should be examined in ail four 
extremities and both carotid arteries. Blood pressure readings 
should be obtained in all four extremities. Infants with obstruc- 
tion to systemic ventricular outflow, such as that found in 
critical aortic stenosis, may hwe diffusely reduced pulse vol- 
ume, whereas in coarctation of the aorta or interruption of the 
aortic arch, there may be differential pulse volume between the 
arms and legs. If the coarctation involves the left subclavian 
artery, and there is a retroesophageal right subclavian artery 
originating below the coarctation site, the only normal pulses 
may be the carotids. 
fn the patient with physical findings of heart failure, a 
diuretic drug such as furosemide may be given before diagnos- 
tic testing is completed. In the infant with heart failure, oxygen 
administration generally is withheld until an anatomic diagno- 
sis can be ascertained. in patients with anatomic outflow 
obstructions, such as hypopiastic left heart syndrome (in which 
the entire systemic outflow is through the ductus arteriosus), 
administration of oxygen may constrict the ductus and reduce 
systemic output. Initial diagnostic testing should include deter- 
mination of the serum concentrations of glucose, caicium and 
hemoglobin because abnomalities in these variables may 
accompany or cause heart failure. A chest radiograph is helpful 
to detect pleural effusion, pneumonia or anatomic abnorrnal- 
ities, such as diaphragmatic hernia. It wi!I also confirm the 
diagnosis of pulrnonay overcirculation. 
The rhythm on the ECG may be helpful In diagnosis 
because tachycardia or bradycardia can cause acute hear? 
failure, and chronic tachparrhythmias of any sort can cause 
"cardio~lyopathy." Occasionally, additional pathognomonic 
abnormalities on rhe ECG are found, such as \vide Q waves in 
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anomalous origin of the left coronary artery from the puimo- 
nary artery. 
Thc essential diagnostic test is e5e uansthoracic Doppler- 
two dimensional echocardiogram. The echocardiographic find- 
ings wi?i fail into one of 3ve major ca~egories that determine 
further management. I) Congeriifal heart disease with a left-to- 
,tight shunt. This condition generzlly presents after the first few 
weeks o:' age (rarely in the first week) and is Initially managed 
with intravenous furosemide. Drug doses may be found in a 
number of excellent reviews (102,103j. Digoxin may &Is0 be 
used (see later). Oxygen generally is withheld because of its 
properties of pulmonary vasodilation and systcmic vasocon- 
striction. 2) Congenital heart disease with sy.~ter?~ic outflow 
obstndction je.g., hypopiastic [eft heart syndrome, interrupted 
aortic arch, coarctation of the aorta). Prostaglandin E, is given 
to dilate the ductus arferiosus, and oxygen is withheld because 
it can constrict the ductus. The infant usually undergoes 
Intubation and hypoventilation to increase pulmonary vascular 
resistance and force blood into the systcrnic circulation. 
Digoxin and a diuretic drug may be given. 3) hbrmally &nc- 
tiorzing heart with dilated chambers, especially the right ventricle 
and right atrium. This condition may indicate a congenital 
cxtracardiac arteriovenous fistula found most commonly in the 
cerebral or hepatic circulation; chronic severe anemia also may 
present with this echocardiographic picture. 4) Pericarciial 
eJ@siori with tamponade. 5 )  Dilated, poorlyjknctiorring heart. A 
correctable cause of the latter condition is anomalous origin of 
the left coronary artery from the pulmonary artery; other 
causes include acute myocarditis and acute presentation of 
chronic cardiornyopathy. 
In the infant or child with acute hearr failure accompanied 
by decreased ventricular function, principles similar 10 those 
described for adults are followed. Diuretic drugs should be 
administered cautiously because an acute decrease in preload 
nay lead to hypotension. The intravenous inotropic agents 
used in children (dobutamine, dopamine, epinephrine, isopm- 
rerenol) are generally similar to those used in adults. In 
equivalent doses, dopamine may be less effective in infants 
hecailse of maturational differences in norepinephrine stores 
(104). Intravenous digoxin may be used. However, in the acute 
setting with changing renal peri~ision and function, as well as 
potentially variable serum potassium add calcium concentra- 
tions, digoxin serirrn concentration and effects may be unpre- 
dictable. The use of digoxin In this setting has been questioned. 
Amrinone has bzen used as both a primard inotropic agent and 
as a systemic vasodilator. Other systemic vasodilators, such as 
sodium nitroprusside, hyclralazine and nitroglycerin: have 
also been used (103). Ventricular assist devices for both the 
right ancl left ventricle are being developed for pediatric use 
jiO5). 
Similar considerations apply to the immediate postopera- 
tive period after stlrgely for congeniral heart disease in which 
acute heart failure and low cardiac outp~lt may occur from 
nlyocardial depression due to myocardial isckcmia related to 
cardiopulmonary bypass, tinavoidable resid~lai defect or peri- 
cardial iamponndc from bleeding. 
Diagnostic EvaEuntion of Acute ,Heart Failure in the 
Fetus, Infant and Child:$ 
Class I 
1. Physical examination, including bIood pressure measure- 
men1 in all extremities 
2. CBC and urinalysis 
3. Blood-seram: glucose, ca!cium, electroiytes, creatinine 
4. Electrocardiogram, chest rndiograph, iracsr5oraric 
Doppler-two dimensional echocardiagram 
L"t.dical Treatment of Acuk Heart Ftki1u.w in the 
Fetus, Iqfant and Child 
Class I 
1. General: inrrwenous iaotropes jexclnding digoxin), in- 
travenous diuretic 
2. @siemic o:i$ow obstmct;on: prostaglandin El, artificial 
ventilation without suppiemental oxygen 
Class 11 
General: digoxin 
Class 111 
Oxygen administration until a definitive diagnosis has been 
established 
Subacute or Chronic Heart Failure 
Infant$ with chronic heart failure may present with difficulty 
in feeding (requiring >20 min to drink a bottle), diaphoresis 
(with damp clothes on awakening from a nap) or poor welghz 
gain (inaSiiity to keep the same growth percentile). Occasion- 
allji, an infant or child with chronic heart failure may present 
with pneumonia; alternatively, hearr failure may be misdiag- 
nosed as pneumonra. In the following five areas, managenlent 
of infants with heart failure may differ from that of adults. 
1. Congestive cardiomyopathy. After ~nitial stabilization, a 
diagnosis or' idiopathic dilated cardiornyopathy must be estab- 
lished by exclusion. li eckocardiograpI;y has riot damonstrated 
normal proximal coronary ar teq  anatomy, cardiac carheceriza- 
lion must be performed. If no anatomic cause is demonstrated, 
nlyocardial biopsy may be performed to diagnose myocarditis. 
In infants and children, rnetabollc and genetic familial causes 
of congestive cardiopathy, such :is carn;r:ne and selenium 
deficiency, are more common than h adults. Therefore, a 
careful family history of early death from heart disease should 
be sought. The management principles and drugs used to treat 
dilated cardiornq.opathy in children arc similar to those used in 
adults. Most recently, ACE inhibitors, such as enalapr~l and 
capropri?, have been used in ~nfants ancl children with symp- 
toms thatale refrzctory to treatrnznt wr!h digoxin and furo- 
semide. In those patiects uirh eutren~ely poor function, plate- 
*Foilow general principles ior r~ilults. 
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let antagonists should be considered as prophylaxis against 
stroke. Although formal outcome studies have not been per- 
formed, it appears at present that no form af therapy in 
children narkediy affects longeviiy (166:). Because the progno- 
sis is so poor i3 many cases, heart transplanrafoi~ should be 
considered. 
2, Congenital heart disease *with a left to right shunt. In an 
inlant with a large left io right shunt, the choice for continued 
medical management is weighed against the severity of the 
heart failure, (he natural history of the defect and the expzcted 
success of operatior.. For example, in the infant with a large 
ventricular septa1 defect, there is approximately a 50% proba- 
bility that the defect will become small enough not to require 
surgical intervention. Therefore, in most instances surgical 
interverition for ventricular septal defect is postponed as long 
as the infant is gaining weight and free of lower respiratory 
tract infection. If the infant still has a large left to right shunt 
after 6 months of age, increasing consideration is given to 
repair of the deleci, especially in the presenze of signiscantly 
elevated pulmonary arteq pressure. 
Medical management in these infants is controversial. Low 
sodium formulas are available, but appropriately controlled 
studies have not been performed to determine their efficacy. A 
diuretic drug such as furosemide generally is given. As long as 
the dose is <2 m@g per day oraliy, excess potassium loss 
generally does not occur. At higher doses, spironolactone 
generally is added, potentially obviating the need for potas- 
sium suppiementation. Despite one recent study in which the 
use of a diuretic drug did not reduce the respiratoq rate in a 
group of 18 infants with a large ventricular septal defea (li)?j, 
many clinicians recommend the use of a diuretic drug In this 
situation (102,103 j. 
The greatest controversy has surrounded the use of digoxin 
in infants with a ieft to right shunr. It has generally been 
accepted that in the premature infant with a patent ductus 
arreriosus, the risk of digoxin toxicity and the lack of demon- 
strated benefit do not justify the use of digoxin. The contro- 
versy cllrrentiy surrounds infants wirh a ventricular septal 
defec~ in whom conrracriliry, as rxeasured by load-independent 
indexes, is frequently normal. The results and recommenda- 
tions have been contradictory. In the study of Gmbail el a!. 
(107), digoxin did not change symptoms, although the combi- 
nation of digoxin and furosemide did provide an increase in 
contractility over that at baseline. In ail but two of the infants, 
right ventricular systolic pressure was <90% of ieft vznrricular 
pressure, and ventricular function appeared to be normal in ail. 
In coatradisfnczion, in the study of Colan and Sanders (!08), 
many patients wirh a large ventricular septal defect ha3 
reduced ventricular function measured by a similar load- 
independent index, and digosin was f w d  to he beneficial. It 
appears that in certain children with a large !eft to right shunt 
and symptomatic heart failure, digoxin nay be of beenfit. 
Finally, conrroversy smro~nds  the use of vasodiiators. IE 
the presence of a large interventric~iiar communication in 
which right and left ventricular sysrolic pressures are ecjua!, the 
amount of ?zft to right shunt is dependent on the BaIance or' 
pulmonary and systemic vascular resistance. Because there are 
no specific vasodilators that agect the pulrnone~j and systemic 
circ~lstlons Ziiflereztially acd in the same direction? it is to be 
expected that some c5ildren with left to right shant given a 
va~odilhiof might impravc and others mighr not. In catherzr- 
ization studies ji09,1 lo), it appears that ca?toprii and enala- 
pril are nos i  beneficial in children with either elevated sys- 
temic vascular resistance (>ZU ~ . / r r , ~ ) ,  or t h o ~ i  without 
narkediy eievated puirnonary arrerioiar resistance (<3.5 
~,'m'j. Thesz infants must he monirored closely for hypoten- 
sion or worsening heart failure. 
3. Eisenmenger's syndrome with heart failure. Pa~ients 
with Eisenmenger's syncirome have elevated pulmonary vascu- 
lar resistance and a communication (either atrial, ventricular 
or ductal) that allows right to left shunting so that systemic 
arterial oxygen samratior? is dependent o r  the balance bemeen 
pulmonary and systemic vascular resistance. if patients with 
Eisenmenger's syndrome are treated xiti; a vasodilator, there 
is a risk that with relatively fixed pulmonary arteriolar resis- 
tance, there will be a greater vasodilating effect on the systemic 
vascularurc, an increase in right to left shunting and a decrease 
in systemic arterial saturation. For this reason, vasodilators 
usiially are not given to patients with Eisenmenger's syndrome 
unless the shunt had been corrected previously. T'ne type of 
heart failure generajly found in patents with Eisenmenger's 
syndrome is right-sided heart failure with tricuspid regurgita- 
tion, hepatornegaiy, peripheral edema and low cardiac output. 
4 diuretic drug may relieve painful hepatic congestion and 
edema. Digoxin is freqrteniiy used, although its benefit has not 
been studied. Phlebotomy to reduce the viscosity of the blood 
has been used in patients with Eisenmenger's syndrome and 
high hernatocriis to decrease sjmptorns of headaches: muscle 
and joint aches, but Its effect on myocardial function is 
undemonstrated. Heart;lang transplantation fhould be coxsid- 
ered in tnose with Eisenrnenger's syndrome. 
4. Heart failure due to al-rhyythmias. Acute paroxysmal 
tachyarrhythmias or 'sradyarrhythmias may cause heart failure, 
and elimination of the arrhythmia is the treatment choice. 
Chronic, incessant tachyarrhythmias (e.g., atrial ectopic tachy- 
cardia, permanent junctional reciprocai;ng tachycardia, atrial 
flutter or ventricular tachycardia) that are present >10% of 
the day may cause chronic heart failure. These arrhythmias 
maj  cause a dilated, poorly functioning heart or diastolic 
dysfunction. The identification of the tachyrhythmia generally 
is not diGcuit. However, in some patients, a right atrial ectopic 
focus tachycardia may masquerade as sinus tachycardia. In 
these patients, atrial ectopic rachycardia is more likely if the 
P wave is negative in lead V, or if the heart rate is >l50% of 
the upper limit of normal for age ( I l l ) .  The causative nature 
of the rachyrhythmia has been dernonsrrated by the eventual 
norrnaliza~ion of cardiac size and function after definitive 
treatment of ",he tachyrhythrnia (112). 
5. Heart failure in the fetus. Weari failure in the fetlrs is 
dernoi~strated by rhe findings of pleura! efiusion, pericardial 
effusion, ascites and skin edema on the fetal echocardiogram. 
Ferni heart failure causzd by congzriita! h e ~ r r  disease us:ialiy is 
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an ominous finding and may be associated with spontaneous 
ahortion. The most common cause for feral heart failure is 
suseai~ed supraventricular tachycardia. Because tke infant may 
be in sinus rkjlthm at the time of the fetal echocardiogram 
(having just had a long episode of supraventricuiar tachycar- 
dia), there must be a high index of suspicion of an arrhythmia 
if there are signs of hear1 failure and the heart is anatomically 
normal. Thih arrhythmia is treated initialjy with digoxin given 
ro :he mother. There hzve been reports of success with 
verapamil, flecainide, procainamide and amiodarone. The 
majority of fetuses with supraventricular tachycardia can be 
treated successfdly, with only a minority requiricg early deliv- 
e,p. 
Diagnostic Evaluation of Subacute or Chronic 
Head Failure in the Fetus, dnj%nt and Child* 
Class 1 
1. General: electrocardiogram, chest radiograph, trans- 
thoracic Doppler-two dimencional echocardiogram (if nor 
previously performed) 
2. Geneml: cardiac aatheterizationlcoronaly arreriography 
to determine coronary anatomy if not established "uy echocar- 
diograrn 
3. General: Holter monitor if no other cause for failure is 
found 
4. General: tests for carnitice, selenium deficiency 
5. Fetus: repeated echocardiogram for paroxysmal arrhyth- 
mia if there is evidence of hydrops fetaiis 
Class I1 
General: myocardial biopsy 
Medical Treatment of Subacute or Chronic ;Yeart 
Failure in the Fetus, Infant and Child* 
Class 1 
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r Initial diagnostic testing should indude CBC, urinalysis, 
strum eiectrolytes, glucose, calcium, creatinine, chest radio- 
graph and ECG. Tne essential diagnostic study is the 
trhnsthoracic Doppler-txlo dimensional echocardiogram. 
e In infants with hcart failure, oxygen administration generally 
is withheld undl an anatomic diagnosis czn be made. 
e Heart faihre dae to congenital heart disease with a ieft to 
right shui~t is managed initially with intravenous hrosemide. 
Oxygen is withheld becailse of its properties of pulnionaq 
vasodilation and systemic vasoconstricrion. 
r infants with heart failure due to cocgenhal heart disease 
with sysiemic outflow obstruction should receive prosta- 
glandin El to dilate :he ductus arteriosus, and oxygen should 
be withheld. 
r A diagnosis of idiopathic dilatec; cardiomyopathy must he 
established by exclusion. i f  echocardiography has not dem- 
ons~rated normal proximal corona9 artery anatomy, cardiac 
catheterization should be performed. If no anatomic cause is 
demonstrdled, n~yocard~al biopsy may be indicated. 
e The management principles and drugs used to treat dilated 
cardiomjopathy in children are vimilar to those used in 
adults. 
e Controversy surrounds the use of digoxin in Infants and 
children, but it may be useful in those with symptomatic 
heart failure. 
r ACE inhibitors are most beneficial in chijdren with either 
ele\ ated systemic vascular resistance or those without nark- 
edly elevated pulmonary vascbiar zesistance. 
e Vasodilators generally are contraigdieated in patients with 
Eisenmenger's syndrome, unless the shunt has been surgi- 
cally corrected. 
m Chronic illcessanr tachyarrhythxias that are present >:O% 
of the day may cause dilated cardiomyopathy and heart 
failure. 
e The most common catse of fetal heart failure is sustained 
supraventricular tach!cardia, which is treated by admin~ster- 
ing digoxin to the mother. 
I. General: diuretic 
2. Congestive cardiom,vopnth,v: digoxin, ACE inhibitor Apnsndk 
5. Fetus: digoxin. specific antiarrhythmic treatment 
Class %I #tug American College qf Cardio!ogy 
1. Congestive cardiomyopathy: platelet antagonists David J. Feiid, Exccutivc Vice President 
2. Left to ~ghi shur,t: digoxin, ACE inhibitor Grace D. Ronan, Assistznr Director, Special Projects 
3. Eisenrneizger:~ syr!rlrome; dipoxin, phlebotomj Neile H. Stewart, Guidelines Coordinator, Special Projects 
Class 111 
EiseitrnetzgerS gndrorne: systemic vasodilator 
Slag Arnencun Heart Assoclnt~on, O$ce 3s SuentiJic A,Yars 
Rodman D. Starke, MD, FACC, Senior Vice President 
Kathryn A. Ta~Ser t ,  PhD, Senior Sc~ence Consultant 
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